BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. The Lancet 2003;362:1907-17. [DOI: 10.1016/s0140-6736(03)14964-1] [Cited by in Crossref: 3076] [Cited by in F6Publishing: 1294] [Article Influence: 161.9] [Reference Citation Analysis]
Number Citing Articles
1 Zhang H, Zhao X, Yu W. Factors Associated with Recurrence of Hepatocellular Carcinoma in 197 Patients Following Transarterial Chemoembolization: A Retrospective Study from a Single Center. Med Sci Monit 2021;27:e929879. [PMID: 34531359 DOI: 10.12659/MSM.929879] [Reference Citation Analysis]
2 Jiang S, Liu Y, Wang L, Duan C, Liu M. A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma. World J Surg Oncol. 2013;11:240. [PMID: 24060218 DOI: 10.1186/1477-7819-11-240] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
3 Tsiambas E, Manaios L, Papanikolopoulos C, Rigopoulos DN, Tsounis D, Karameris A, Soultati A, Koliopoulou A, Kravvaritis C, Sergentanis T. Chromogenic in situ hybridization analysis of Epidermal Growth Factor Receptor gene/chromosome 7 numerical aberrations in hepatocellular carcinoma based on tissue microarrays. Pathol Oncol Res. 2009;15:511-520. [PMID: 19145479 DOI: 10.1007/s12253-008-9146-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
4 Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitsu H. The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. PLoS One 2016;11:e0146456. [PMID: 26745625 DOI: 10.1371/journal.pone.0146456] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
5 Welker MW, Trojan J. Anti-angiogenesis in hepatocellular carcinoma treatment: Current evidence and future perspectives. World J Gastroenterol 2011; 17(26): 3075-3081 [PMID: 21912449 DOI: 10.3748/wjg.v17.i26.3075] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
6 Molina V, Sampson-Dávila J, Ferrer J, Fondevila C, Díaz Del Gobbo R, Calatayud D, Bruix J, García-Valdecasas JC, Fuster J. Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study. Surg Endosc 2018;32:2345-54. [PMID: 29218665 DOI: 10.1007/s00464-017-5930-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
7 Bubici C, Papa S. JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol 2014;171:24-37. [PMID: 24117156 DOI: 10.1111/bph.12432] [Cited by in Crossref: 212] [Cited by in F6Publishing: 189] [Article Influence: 26.5] [Reference Citation Analysis]
8 Zhang N, Wang L, Chai ZT, Zhu ZM, Zhu XD, Ma DN, Zhang QB, Zhao YM, Wang M, Ao JY, Ren ZG, Gao DM, Sun HC, Tang ZY. Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling. PLoS One 2014;9:e115949. [PMID: 25542041 DOI: 10.1371/journal.pone.0115949] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
9 Soubrane O, Goumard C, Laurent A, Tranchart H, Truant S, Gayet B, Salloum C, Luc G, Dokmak S, Piardi T, Cherqui D, Dagher I, Boleslawski E, Vibert E, Sa Cunha A, Belghiti J, Pessaux P, Boelle PY, Scatton O. Laparoscopic resection of hepatocellular carcinoma: a French survey in 351 patients. HPB (Oxford) 2014;16:357-65. [PMID: 23879788 DOI: 10.1111/hpb.12142] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 8.0] [Reference Citation Analysis]
10 Xiang X, Deng L, Xiong R, Xiao D, Chen Z, Yang F, Liu K, Feng G. Tex10 is upregulated and promotes cancer stem cell properties and chemoresistance in hepatocellular carcinoma. Cell Cycle 2018;17:1310-8. [PMID: 30045663 DOI: 10.1080/15384101.2018.1480208] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
11 Scalera A, Tarantino G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol 2014; 20(28): 9217-9228 [PMID: 25071314 DOI: 10.3748/wjg.v20.i28.9217] [Cited by in F6Publishing: 36] [Reference Citation Analysis]
12 Paul SB, Sharma H. Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol 2014;4:S112-21. [PMID: 25755602 DOI: 10.1016/j.jceh.2014.03.048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
13 Höpfner M, Schuppan D, Scherübl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008; 14(1): 1-14 [PMID: 18176955 DOI: 10.3748/wjg.14.1] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 74] [Article Influence: 5.1] [Reference Citation Analysis]
14 Zamboni CG, Kozielski KL, Vaughan HJ, Nakata MM, Kim J, Higgins LJ, Pomper MG, Green JJ. Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma. J Control Release 2017;263:18-28. [PMID: 28351668 DOI: 10.1016/j.jconrel.2017.03.384] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 6.4] [Reference Citation Analysis]
15 Almhanna K, Philip PA. Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma. Onco Targets Ther 2009;2:261-7. [PMID: 20616913 DOI: 10.2147/ott.s5548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
16 Tajiri K, Futsukaichi Y, Kobayashi S, Nagata K, Yasumura S, Takahara T, Minemura M, Yasuda I. Efficacy of on-demand intrahepatic arterial therapy in combination with sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther 2019;12:2205-14. [PMID: 30988625 DOI: 10.2147/OTT.S191741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Liang C, Xu Y, Li G, Zhao T, Xia F, Li G, Zhang D, Wu J. Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis. Onco Targets Ther 2017;10:417-28. [PMID: 28176915 DOI: 10.2147/OTT.S127202] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
18 Hernandez-Gea V, Turon F, Berzigotti A, Villanueva A. Management of small hepatocellular carcinoma in cirrhosis: Focus on portal hypertension. World J Gastroenterol 2013; 19(8): 1193-1199 [PMID: 23482437 DOI: 10.3748/wjg.v19.i8.1193] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
19 Xiao J, Li Y, Jiang Q, Sun L, Henderson F Jr, Wang Y, Jiang X, Li G, Chen N. Hepatic arterial phase and portal venous phase computed tomography for dose calculation of stereotactic body radiation therapy plans in liver cancer: a dosimetric comparison study. Radiat Oncol 2013;8:264. [PMID: 24209300 DOI: 10.1186/1748-717X-8-264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
20 Kodama S, Yamazaki Y, Negishi M. Pregnane X Receptor Represses HNF4α Gene to Induce Insulin-Like Growth Factor-Binding Protein IGFBP1 that Alters Morphology of and Migrates HepG2 Cells. Mol Pharmacol 2015;88:746-57. [PMID: 26232425 DOI: 10.1124/mol.115.099341] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
21 Hai H, Tamori A, Kawada N. Role of hepatitis B virus DNA integration in human hepatocarcinogenesis. World J Gastroenterol 2014; 20(20): 6236-6243 [PMID: 24876744 DOI: 10.3748/wjg.v20.i20.6236] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 52] [Article Influence: 7.4] [Reference Citation Analysis]
22 Swan RZ, Sindram D, Martinie JB, Iannitti DA. Operative microwave ablation for hepatocellular carcinoma: complications, recurrence, and long-term outcomes. J Gastrointest Surg. 2013;17:719-729. [PMID: 23404173 DOI: 10.1007/s11605-013-2164-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]
23 Pan FY, Zhang SZ, Xu N, Meng FL, Zhang HX, Xue B, Han X, Li CJ. Beta-catenin signaling involves HGF-enhanced HepG2 scattering through activating MMP-7 transcription. Histochem Cell Biol 2010;134:285-95. [PMID: 20677010 DOI: 10.1007/s00418-010-0729-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
24 Chen X, Ding G, Gao Q, Sun J, Zhang Q, Du L, Qiu Z, Wang C, Zheng F, Sun B, Ni J, Feng Z, Zhu J. A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma. PLoS One 2013;8:e63093. [PMID: 23675455 DOI: 10.1371/journal.pone.0063093] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
25 Henrici A, Montalbano R, Neureiter D, Krause M, Stiewe T, Slater EP, Quint K, Ocker M, Di Fazio P. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Mol Carcinog 2015;54:585-97. [PMID: 24375802 DOI: 10.1002/mc.22122] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
26 Jae HJ, Chung JW, Park HS, Lee MJ, Lee KC, Kim HC, Yoon JH, Chung H, Park JH. The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: in vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model. Korean J Radiol. 2009;10:596-603. [PMID: 19885316 DOI: 10.3348/kjr.2009.10.6.596] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
27 Malek NP, Schmidt S, Huber P, Manns MP, Greten TF. The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int 2014;111:101-6. [PMID: 24622679 DOI: 10.3238/arztebl.2014.0101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 32] [Article Influence: 0.7] [Reference Citation Analysis]
28 Dong D, Mu Z, Zhao C, Sun M. ZFAS1: a novel tumor-related long non-coding RNA. Cancer Cell Int 2018;18:125. [PMID: 30186041 DOI: 10.1186/s12935-018-0623-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
29 Qian GJ, Wang N, Shen Q, Sheng YH, Zhao JQ, Kuang M, Liu GJ, Wu MC. Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellular carcinoma: experimental and clinical studies. Eur Radiol. 2012;22:1983-1990. [PMID: 22544225 DOI: 10.1007/s00330-012-2442-1] [Cited by in Crossref: 103] [Cited by in F6Publishing: 100] [Article Influence: 10.3] [Reference Citation Analysis]
30 Matsuda Y, Fukumoto M. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol 2011;44:183-9. [PMID: 22179180 DOI: 10.1007/s00795-011-0558-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
31 Ang SF, Ng ES, Li H, Ong YH, Choo SP, Ngeow J, Toh HC, Lim KH, Yap HY, Tan CK, Ooi LL, Cheow PC, Chung AY, Chow PK, Foo KF, Tan MH. The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. PLoS One. 2015;10:e0118658. [PMID: 25830231 DOI: 10.1371/journal.pone.0118658] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
32 Liu YS, Ou MC, Tsai YS, Lin XZ, Wang CK, Tsai HM, Chuang MT. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma. Korean J Radiol. 2015;16:125-132. [PMID: 25598680 DOI: 10.3348/kjr.2015.16.1.125] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
33 Pham BV, Phan HH, Ngo LL, Nguyen HTT, Le KV, Dinh TC, Bac ND. A Rare Colonic Metastasis Case from Hepatocellular Carcinoma. Open Access Maced J Med Sci 2019;7:4368-71. [PMID: 32215096 DOI: 10.3889/oamjms.2019.837] [Reference Citation Analysis]
34 Komatsu S, Brustia R, Goumard C, Perdigao F, Soubrane O, Scatton O. Laparoscopic versus open major hepatectomy for hepa-tocellular carcinoma: a matched pair analysis. Surg Endosc. 2015; Epub ahead of print. [PMID: 26194255 DOI: 10.1007/-s00464-015-4422-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Tang KF, Chen M, Xie J, Song GB, Shi YS, Liu Q, Mei ZC, Steinle A, Ren H. Inhibition of hepatitis B virus replication by small interference RNA induces expression of MICA in HepG2.2.15 cells. Med Microbiol Immunol. 2009;198:27-32. [PMID: 18685862 DOI: 10.1007/s00430-008-0101-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
36 Marzi L, Villa E. Prognostic signatures from hepatocellular carcinoma biopsy. Hepat Oncol 2017;4:65-8. [PMID: 30191054 DOI: 10.2217/hep-2017-0016] [Reference Citation Analysis]
37 Matsuda Y, Wakai T, Kubota M, Takamura M, Yamagiwa S, Aoyagi Y, Osawa M, Fujimaki S, Sanpei A, Genda T. Clinical significance of cell cycle inhibitors in hepatocellular carcinoma. Med Mol Morphol. 2013;46:185-192. [PMID: 23640750 DOI: 10.1007/s00795-013-0047-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
38 Lee JS. The mutational landscape of hepatocellular carcinoma. Clin Mol Hepatol 2015;21:220-9. [PMID: 26523267 DOI: 10.3350/cmh.2015.21.3.220] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 9.0] [Reference Citation Analysis]
39 Ettorre GM, Levi Sandri GB, Santoro R, Vennarecci G, Lepiane P, Colasanti M, Felli E, de Werra E, Colace L, D'Offizi G, Montalbano M, Visco U, Maritti M, Antonini M, Santoro E. Laparoscopic liver resection for hepatocellular carcinoma in cirrhotic patients: single center experience of 90 cases. Hepatobiliary Surg Nutr 2015;4:320-4. [PMID: 26605279 DOI: 10.3978/j.issn.2304-3881.2015.06.13] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
40 Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Yu D, Meyer T, Patch DW, Burroughs AK. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2006;32:594-606. [PMID: 17045407 DOI: 10.1016/j.ctrv.2006.08.002] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
41 Shiozawa K, Watanabe M, Ikehara T, Matsukiyo Y, Kogame M, Kishimoto Y, Okubo Y, Makino H, Tsukamoto N, Igarashi Y, Sumino Y. Comparison of percutaneous radiofrequency ablation and CyberKnife® for initial solitary hepatocellular carcinoma: A pilot study. World J Gastroenterol 2015; 21(48): 13490-13499 [PMID: 26730160 DOI: 10.3748/wjg.v21.i48.13490] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
42 Lee S, Cho YY, Cho EJ, Yu SJ, Lee JH, Yoon JH, Kim YJ. Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK. Int J Mol Med 2018;42:2551-9. [PMID: 30106087 DOI: 10.3892/ijmm.2018.3807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
43 Li J, Liu W, Zhu W, Wu Y, Wu B. Transcatheter hepatic arterial chemoembolization and sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials. Oncotarget. 2017;8:59601-59608. [PMID: 28938663 DOI: 10.18632/oncotarget.19334] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
44 Jiang X, Feng K, Zhang Y, Li Z, Zhou F, Dou H, Wang T. Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma. Oncotarget 2015;6:12340-56. [PMID: 25895026 DOI: 10.18632/oncotarget.3656] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
45 Yang H, Woo HY, Lee SK, Han JW, Jang B, Nam HC, Lee HL, Lee SW, Song DS, Song MJ, Oh JS, Chun HJ, Jang JW, Lozada A, Bae SH, Choi JY, Yoon SK. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. Clin Mol Hepatol. 2017;23:128-137. [PMID: 28494528 DOI: 10.3350/cmh.2016.0071] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
46 Hao QQ, Chen GY, Zhang JH, Sheng JH, Gao Y. Diagnostic value of long noncoding RNAs for hepatocellular carcinoma: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 2017;96:e7496. [PMID: 28700498 DOI: 10.1097/md.0000000000007496] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
47 Wang N, Guan Q, Wang K, Zhu B, Yuan W, Zhao P, Wang X, Zhao Y. TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis. Med Oncol. 2011;28:1038-1043. [PMID: 20632218 DOI: 10.1007/s12032-010-9620-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
48 Shi JH, Line PD. Effect of liver regeneration on malignant hepatic tumors. World J Gastroenterol 2014; 20(43): 16167-16177 [PMID: 25473170 DOI: 10.3748/wjg.v20.i43.16167] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
49 Schulze-Bergkamen H, Fleischer B, Schuchmann M, Weber A, Weinmann A, Krammer PH, Galle PR. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC Cancer 2006;6:232. [PMID: 17014711 DOI: 10.1186/1471-2407-6-232] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 4.4] [Reference Citation Analysis]
50 Kim SH, Choi SB, Lee JG, Kim SU, Park MS, Kim do Y, Choi JS, Kim KS. Prognostic factors and 10-year survival in patients with hepatocellular carcinoma after curative hepatectomy. J Gastrointest Surg. 2011;15:598-607. [PMID: 21336497 DOI: 10.1007/s11605-011-1452-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
51 Zhang JQ, Li YM, Liu T, He WT, Chen YT, Chen XH, Li X, Zhou WC, Yi JF, Ren ZJ. Antitumor effect of matrine in human hepatoma G2 cells by inducing apoptosis and autophagy. World J Gastroenterol 2010; 16(34): 4281-4290 [PMID: 20818811 DOI: 10.3748/wjg.v16.i34.4281] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 77] [Article Influence: 7.2] [Reference Citation Analysis]
52 Ma CQ, Yang Y, Wang JM, Du GS, Shen Q, Liu Y, Zhang J, Hu JL, Zhu P, Qi WP, Qian YW, Fu Y. The aPKCι blocking agent ATM negatively regulates EMT and invasion of hepatocellular carcinoma. Cell Death Dis 2014;5:e1129. [PMID: 24651432 DOI: 10.1038/cddis.2014.91] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
53 Lee SH, Song IH, Noh R, Kang HY, Kim SB, Ko SY, Lee ES, Kim SH, Lee BS, Kim AN, Chae HB, Kim HS, Lee TH, Kang YW, Lee JD, Lee HY. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. BMC Cancer 2015;15:236. [PMID: 25885683 DOI: 10.1186/s12885-015-1273-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
54 Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol 2012; 1(6): 174-183 [PMID: 24175223 DOI: 10.5501/wjv.v1.i6.174] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
55 Shao Q, Ren P, Li Y, Peng B, Dai L, Lei N, Yao W, Zhao G, Li L, Zhang J. Autoantibodies against glucose-regulated protein 78 as serological diagnostic biomarkers in hepatocellular carcinoma. Int J Oncol. 2012;41:1061-1067. [PMID: 22692946 DOI: 10.3892/ijo.2012.1515] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
56 Cabibbo G, Latteri F, Antonucci M, Craxì A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:159-69. [DOI: 10.1038/ncpgasthep1357] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
57 Rodgers SK, Fetzer DT, Gabriel H, Seow JH, Choi HH, Maturen KE, Wasnik AP, Morgan TA, Dahiya N, O'Boyle MK, Kono Y, Sirlin CB, Kamaya A. Role of US LI-RADS in the LI-RADS Algorithm. Radiographics 2019;39:690-708. [PMID: 31059393 DOI: 10.1148/rg.2019180158] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
58 Zhou Y, Si X, Wu L, Su X, Li B, Zhang Z. Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies. World J Surg Oncol. 2011;9:108. [PMID: 21933440 DOI: 10.1186/1477-7819-9-108] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
59 Yoo DJ, Chung YH, Lee YS, Kim SE, Jin YJ, Lee YM, Kim MJ. Sigmoid colon metastasis from hepatocellular carcinoma. Korean J Hepatol 2010;16:397-400. [PMID: 21415584 DOI: 10.3350/kjhep.2010.16.4.397] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
60 Araújo OC, Rosa AS, Fernandes A, Niel C, Villela-Nogueira CA, Pannain V, Araujo NM. RASSF1A and DOK1 Promoter Methylation Levels in Hepatocellular Carcinoma, Cirrhotic and Non-Cirrhotic Liver, and Correlation with Liver Cancer in Brazilian Patients. PLoS One 2016;11:e0153796. [PMID: 27078152 DOI: 10.1371/journal.pone.0153796] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
61 Kang D, Han Z, Oh GH, Joo Y, Choi HJ, Song JJ. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib. Yonsei Med J 2017;58:899-909. [PMID: 28792132 DOI: 10.3349/ymj.2017.58.5.899] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
62 Yu Q, Gao K. CLEC4M overexpression inhibits progression and is associated with a favorable prognosis in hepatocellular carcinoma. Mol Med Rep 2020;22:2245-52. [PMID: 32705212 DOI: 10.3892/mmr.2020.11336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Raevskaya O, Appelman H, Razumilava N. A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma. Curr Hepatol Rep 2020;19:478-85. [PMID: 33415066 DOI: 10.1007/s11901-020-00556-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Dong TS, Jacobs JP, Agopian V, Pisegna JR, Ayoub W, Durazo F, Enayati P, Sundaram V, Benhammou JN, Noureddin M, Choi G, Lagishetty V, Fiehn O, Goodman MT, Elashoff D, Hussain SK. Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis. Dig Dis Sci 2021. [PMID: 34799768 DOI: 10.1007/s10620-021-07299-2] [Reference Citation Analysis]
65 Hijona E, Banales JM, Hijona L, Medina JF, Arenas J, Herreros-Villanueva M, Aldazabal P, Bujanda L. Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models. Cancer Cell Int 2012;12:5. [PMID: 22353776 DOI: 10.1186/1475-2867-12-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
66 He C, Zhang Y, Cai Z, Lin X. The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy. Cancer Manag Res 2019;11:1391-400. [PMID: 30863150 DOI: 10.2147/CMAR.S190545] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
67 Mikuriya Y, Tashiro H, Kobayashi T, Kuroda S, Abe T, Hashimoto M, Ohdan H. Clinicopathological features of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Langenbecks Arch Surg 2015;400:471-6. [PMID: 25744657 DOI: 10.1007/s00423-015-1295-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
68 Song MJ. Bae SH, Lee SW, Song DS, Kim HY, Yoo IeR, Choi JI, Lee YJ, Chun HJ, Lee HG, Choi JY, Yoon SK. 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:865-873. [PMID: 23436073 DOI: 10.1007/s00259-013-2366-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
69 Božin T, Mustapić S, Bokun T, Patrlj L, Rakić M, Aralica G, Kujundžić M, Trkulja V, Grgurević I. Albi Score as a Predictor of Survival in Patients with Compensated Cirrhosis Resected for Hepatocellular Carcinoma: Exploratory Evaluation in Relationship to Palbi and Meld Liver Function Scores. Acta Clin Croat 2018;57:292-300. [PMID: 30431722 DOI: 10.20471/acc.2018.57.02.09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
70 Yeh CN, Wu RC, Cheng CT, Tsai CY, Chang YR, Yeh TS, Wu TH, Lee WC, Chiang KC. HO-1 is a favorable prognostic factor for HBV-HCC patients who underwent hepatectomy. Cancer Manag Res 2018;10:6049-59. [PMID: 30538554 DOI: 10.2147/CMAR.S186931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
71 Lin SM, Lu SN, Chen PT, Jeng LB, Chen SC, Hu CT, Yang SS, Le Berre MA, Liu X, Mitchell DY, Prins K, Grevel J, Peña CA, Meinhardt G. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. Hepatol Int 2017;11:199-208. [PMID: 27909950 DOI: 10.1007/s12072-016-9774-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
72 Kim T, Kim BW, Wang HJ, Lee HY, Won JH, Kim J, Hu XG, Sim J, Bang JB, Kim YB. Quantitative Assessment of the Portal Pressure for the Liver Surgery Using Serological Tests. Ann Surg 2016;264:330-8. [PMID: 26587849 DOI: 10.1097/SLA.0000000000001460] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
73 Zhang L, Wang H, Yang T, Su Z, Fang D, Wang Y, Fang J, Hou X, Le Y, Chen K, Wang JM, Su SB, Lin Q, Zhou Q. Formylpeptide receptor 1 mediates the tumorigenicity of human hepatocellular carcinoma cells. Oncoimmunology 2016;5:e1078055. [PMID: 27057451 DOI: 10.1080/2162402X.2015.1078055] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
74 Hai Y, Savsani E, Chong W, Eisenbrey J, Lyshchik A. Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:5162-79. [PMID: 34410432 DOI: 10.1007/s00261-021-03248-9] [Reference Citation Analysis]
75 Lin G, Sun W, Yang Z, Guo J, Liu H, Liang J. Hypoxia induces the expression of TET enzymes in HepG2 cells. Oncol Lett 2017;14:6457-62. [PMID: 29163682 DOI: 10.3892/ol.2017.7063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
76 Facciuto ME, Rochon C, Pandey M, Rodriguez-Davalos M, Samaniego S, Wolf DC, Kim-Schluger L, Rozenblit G, Sheiner PA. Surgical dilemma: liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and outwith Milan criteria. HPB (Oxford) 2009;11:398-404. [PMID: 19768144 DOI: 10.1111/j.1477-2574.2009.00073.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Yang JH, Zhang H, Chen XB, Chen G, Wang X. Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations. World J Gastroenterol 2013; 19(24): 3861-3865 [PMID: 23840126 DOI: 10.3748/wjg.v19.i24.3861] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
78 Davila JA, Kramer JR, Duan Z, Richardson PA, Tyson GL, Sada YH, Kanwal F, El-Serag HB. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013;57:1858-1868. [PMID: 23359313 DOI: 10.1002/hep.26287] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
79 Lee SY, Konstantinidis IT, Eaton AA, Gönen M, Kingham TP, D'Angelica MI, Allen PJ, Fong Y, DeMatteo RP, Jarnagin WR. Predicting recurrence patterns after resection of hepatocellular cancer. HPB (Oxford) 2014;16:943-53. [PMID: 25041404 DOI: 10.1111/hpb.12311] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
80 Schoenberg MB, Hao J, Bucher JN, Miksch RC, Anger HJW, Mayer B, Mayerle J, Neumann J, Guba MO, Werner J, Bazhin AV. Perivascular Tumor-Infiltrating Leukocyte Scoring for Prognosis of Resected Hepatocellular Carcinoma Patients. Cancers (Basel) 2018;10:E389. [PMID: 30340430 DOI: 10.3390/cancers10100389] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
81 Facciuto ME, Rochon C, Pandey M, Rodriguez-Davalos M, Samaniego S, Wolf DC, Kim-Schluger L, Rozenblit G, Sheiner PA. Surgical dilemma: liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and outwith Milan criteria. HPB (Oxford) 2009;11:398-404. [PMID: 19768144 DOI: 10.1111/j.1477-2574.2009.00073.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
82 Yin L, Wang Y, Guo X, Xu C, Yu G. Comparison of gene expression in liver regeneration and hepatocellular carcinoma formation. Cancer Manag Res 2018;10:5691-708. [PMID: 30532592 DOI: 10.2147/CMAR.S172945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
83 Jia JB, Wang WQ, Sun HC, Zhu XD, Liu L, Zhuang PY, Zhang JB, Zhang W, Xu HX, Kong LQ, Lu L, Wu WZ, Wang L, Tang ZY. High expression of macrophage colony-stimulating factor-1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection. Oncologist 2010;15:732-43. [PMID: 20551429 DOI: 10.1634/theoncologist.2009-0170] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
84 Wang X, Xie G, Zhao A, Zheng X, Huang F, Wang Y, Yao C, Jia W, Liu P. Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis. J Proteome Res 2016;15:1126-34. [PMID: 25964117 DOI: 10.1021/acs.jproteome.5b00217] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 6.5] [Reference Citation Analysis]
85 Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol 2015; 7(8): 1041-1053 [PMID: 26052393 DOI: 10.4254/wjh.v7.i8.1041] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
86 Kusakabe Y, Chiba T, Oshima M, Koide S, Rizq O, Aoyama K, Ao J, Kaneko T, Kanzaki H, Kanayama K, Maeda T, Saito T, Nakagawa R, Kobayashi K, Kiyono S, Nakamura M, Ogasawara S, Suzuki E, Nakamoto S, Yasui S, Mikata R, Muroyama R, Kanda T, Maruyama H, Kato J, Mimura N, Ma A, Jin J, Zen Y, Otsuka M, Kaneda A, Iwama A, Kato N. EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma. Sci Rep 2021;11:21396. [PMID: 34725436 DOI: 10.1038/s41598-021-00889-0] [Reference Citation Analysis]
87 Yang X, Qiu Z, Ran R, Cui L, Luo X, Wu M, Tan WF, Jiang X. Prognostic importance of bile duct invasion in surgical resection with curative intent for hepatocellular carcinoma using PSM analysis. Oncol Lett. 2018;16:3593-3602. [PMID: 30127966 DOI: 10.3892/ol.2018.9108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
88 Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol 2015; 7(3): 406-424 [PMID: 25848467 DOI: 10.4254/wjh.v7.i3.406] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 9.7] [Reference Citation Analysis]
89 Chen D, Siddiq A, Emdad L, Rajasekaran D, Gredler R, Shen XN, Santhekadur PK, Srivastava J, Robertson CL, Dmitriev I. Insulin-like growth factor-binding protein-7 (IGFBP7): a promising gene therapeutic for hepatocellular carcinoma (HCC). Mol Ther. 2013;21:758-766. [PMID: 23319057 DOI: 10.1038/mt.2012.282] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
90 Inokawa Y, Nomoto S, Hishida M, Hayashi M, Kanda M, Nishikawa Y, Takeda S, Sugimoto H, Fujii T, Yamada S, Kodera Y. Detection of doublecortin domain-containing 2 (DCDC2), a new candidate tumor suppressor gene of hepatocellular carcinoma, by triple combination array analysis. J Exp Clin Cancer Res 2013;32:65. [PMID: 24034596 DOI: 10.1186/1756-9966-32-65] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
91 Forner A, Rodríguez-Lopez C, Reig M. Natural history and staging for hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2012;1:183-5. [PMID: 31186883 DOI: 10.1002/cld.129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
92 Gül-Klein S, Kästner A, Haber PK, Krenzien F, Wabitsch S, Krannich A, Andreou A, Eurich D, Tacke F, Horst D, Pratschke J, Schmelzle M. Recurrence of Hepatocellular Carcinoma After Liver Transplantation is Associated with Episodes of Acute Rejections. J Hepatocell Carcinoma 2021;8:133-43. [PMID: 33777855 DOI: 10.2147/JHC.S292010] [Reference Citation Analysis]
93 Fages A, Duarte-Salles T, Stepien M, Ferrari P, Fedirko V, Pontoizeau C, Trichopoulou A, Aleksandrova K, Tjønneland A, Olsen A, Clavel-Chapelon F, Boutron-Ruault MC, Severi G, Kaaks R, Kuhn T, Floegel A, Boeing H, Lagiou P, Bamia C, Trichopoulos D, Palli D, Pala V, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita HB, Peeters PH, Weiderpass E, Agudo A, Molina-Montes E, Huerta JM, Ardanaz E, Dorronsoro M, Sjöberg K, Ohlsson B, Khaw KT, Wareham N, Travis RC, Schmidt JA, Cross A, Gunter M, Riboli E, Scalbert A, Romieu I, Elena-Herrmann B, Jenab M. Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort. BMC Med 2015;13:242. [PMID: 26399231 DOI: 10.1186/s12916-015-0462-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 7.6] [Reference Citation Analysis]
94 Tu T, Budzinska MA, Maczurek AE, Cheng R, Di Bartolomeo A, Warner FJ, McCaughan GW, McLennan SV, Shackel NA. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci. 2014;15:9422-9458. [PMID: 24871369 DOI: 10.3390/ijms15069422] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
95 Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2017;15:1791-9. [PMID: 28579181 DOI: 10.1016/j.cgh.2017.05.036] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
96 Marsella M, Ricchi P. Thalassemia and hepatocellular carcinoma: links and risks. J Blood Med 2019;10:323-34. [PMID: 31572038 DOI: 10.2147/JBM.S186362] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
97 Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML, Joos S, Devens F, Lichter P, Rieker RJ, Trojan J, Chung HJ, Levens DL, Zörnig M. Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology 2009;50:1121-9. [PMID: 19637194 DOI: 10.1002/hep.23098] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 4.9] [Reference Citation Analysis]
98 Yan HX, Wu HP, Zhang HL, Ashton C, Tong C, Wu H, Qian QJ, Wang HY, Ying QL. p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release. J Hepatol 2013;59:762-8. [PMID: 23714159 DOI: 10.1016/j.jhep.2013.05.029] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
99 Csepregi A, Röcken C, Hoffmann J, Gu P, Saliger S, Müller O, Schneider-Stock R, Kutzner N, Roessner A, Malfertheiner P. APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134:579-589. [PMID: 17973119 DOI: 10.1007/s00432-007-0321-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
100 Tanaka S, Miyanishi K, Kobune M, Kawano Y, Hoki T, Kubo T, Hayashi T, Sato T, Sato Y, Takimoto R. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. J Gastroenterol. 2013;48:1249-1258. [PMID: 23329365 DOI: 10.1007/s00535-012-0739-0] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
101 Bargellini I, Battaglia V, Bozzi E, Lauretti DL, Lorenzoni G, Bartolozzi C. Radiological diagnosis of hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:137-48. [PMID: 27508183 DOI: 10.2147/JHC.S44379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
102 Robbins CT, Tollefson TN, Rode KD, Erlenbach JA, Ardente AJ. New insights into dietary management of polar bears (Ursus maritimus) and brown bears (U. arctos). Zoo Biol 2021. [PMID: 34793606 DOI: 10.1002/zoo.21658] [Reference Citation Analysis]
103 Fenoglio L, Serraino C, Castagna E, Cardellicchio A, Pomero F, Grosso M, Senore C. Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. World J Gastroenterol 2013; 19(21): 3207-3216 [PMID: 23745022 DOI: 10.3748/wjg.v19.i21.3207] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
104 Huang JH, Gao F, Gu YK, Li WQ, Lu LW. Combined treatment of hepatocellular carcinoma with partial splenic embolization and transcatheter hepatic arterial chemoembolization. World J Gastroenterol 2007; 13(48): 6593-6597 [PMID: 18161933 DOI: 10.3748/wjg.v13.i48.6593] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
105 Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, Yang J. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol. 2010;10:78. [PMID: 20618937 DOI: 10.1186/1471-230x-10-78.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Sarkar D. AEG-1/MTDH/LYRIC in liver cancer. Adv Cancer Res 2013;120:193-221. [PMID: 23889992 DOI: 10.1016/B978-0-12-401676-7.00007-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
107 Mínguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, Mandeli J, Sia D, April C, Fan JB, Lachenmayer A, Savic R, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Friedman SL, Llovet JM. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 2011;55:1325-31. [PMID: 21703203 DOI: 10.1016/j.jhep.2011.02.034] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 8.5] [Reference Citation Analysis]
108 Xia F, Wu LL, Lau WY, Huan HB, Wen XD, Ma KS, Li XW, Bie P. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. World J Gastroenterol 2016; 22(23): 5384-5392 [PMID: 27340354 DOI: 10.3748/wjg.v22.i23.5384] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
109 Li W, Lebrun DG, Li M. The expression and functions of microRNAs in pancreatic adenocarcinoma and hepatocellular carcinoma. Chin J Cancer. 2011;30:540-550. [PMID: 21801602 DOI: 10.5732/cjc.011.10197] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
110 Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212. [PMID: 15887976 DOI: 10.1007/bf03260065] [Cited by in Crossref: 54] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
111 Mitchell J, Tinkey PT, Avritscher R, Van Pelt C, Eskandari G, Konnath George S, Xiao L, Cressman E, Morris JS, Rashid A, Kaseb AO, Amin HM, Uthamanthil R. Validation of a Preclinical Model of Diethylnitrosamine-Induced Hepatic Neoplasia in Yucatan Miniature Pigs. Oncology 2016;91:90-100. [PMID: 27305144 DOI: 10.1159/000446074] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
112 Bruno S, Savojardo D, Almasio PL, Mondelli MU. Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. Hepat Med 2011;3:21-8. [PMID: 24367218 DOI: 10.2147/HMER.S16991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
113 Gao S, Yang RJ, Dong JH. Hepatocellular carcinoma with blood supply from parasitized omental artery: angiographic appearance and chemoembolization. Chin J Cancer Res 2012;24:207-12. [PMID: 23359452 DOI: 10.1007/s11670-012-0207-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
114 Jin C, Li H, He Y, He M, Bai L, Cao Y, Song W, Dou K. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. J Cancer Res Clin Oncol. 2010;136:267-274. [PMID: 19693537 DOI: 10.1007/500432-009-0658-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Ding X, Wang K, Wang H, Zhang G, Liu Y, Yang Q, Chen W, Hu S. High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection. J Gastrointest Surg. 2012;16:828-836. [PMID: 22072303 DOI: 10.1007/s11605-011-1775-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
116 Wu N, Zhang YL, Wang HT, Li DW, Dai HJ, Zhang QQ, Zhang J, Ma Y, Xia Q, Bian JM, Hang HL. Overexpression of hepatocyte nuclear factor 4α in human mesenchymal stem cells suppresses hepatocellular carcinoma development through Wnt/β-catenin signaling pathway downregulation. Cancer Biol Ther 2016;17:558-65. [PMID: 27124543 DOI: 10.1080/15384047.2016.1177675] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
117 Vidal-Cevallos P, Chavez-Tapia N. Very-early-stage Hepatocellular Carcinoma, Are We at Long Last on Route for Achieving Better Patient Outcomes? J Clin Transl Hepatol 2021;9:141-2. [PMID: 34007794 DOI: 10.14218/JCTH.2021.00137] [Reference Citation Analysis]
118 Liu Y, Wang Y, Hu Y, Ge S, Li K, Wang S, Li L. The apoptotic inducible effects of salicylic acid on hepatoma cell line: relationship with nitric oxide signaling. J Cell Commun Signal 2017;11:245-53. [PMID: 28185215 DOI: 10.1007/s12079-017-0380-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
119 Hatab HM, Abdel Hamid FF, Soliman AF, Al-Shafie TA, Ismail YM, El-Houseini ME. A combined treatment of curcumin, piperine, and taurine alters the circulating levels of IL-10 and miR-21 in hepatocellular carcinoma patients: a pilot study. J Gastrointest Oncol 2019;10:766-76. [PMID: 31392057 DOI: 10.21037/jgo.2019.03.07] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
120 Sacco R, Granito A, Bargellini I, Zolfino T, Saitta C, Marzi L, Tapete G, Bresci G, Marinelli S, Tovoli F, Attardo S, Rossi M, Urbani L, Marchi S, Buccianti P, Cabibbo G. Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study. Future Oncol 2018;14:3049-58. [PMID: 30091371 DOI: 10.2217/fon-2018-0281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
121 Tan XW, Xia H, Xu JH, Cao JG. Induction of apoptosis in human liver carcinoma HepG2 cell line by 5-allyl-7-gen-difluoromethylenechrysin. World J Gastroenterol 2009; 15(18): 2234-2239 [PMID: 19437563 DOI: 10.3748/wjg.15.2234] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
122 Cho Y, Lee JH, Lee DH, Cho EJ, Yu SJ, Yi NJ, Lee KW, Kim YJ, Yoon JH, Suh KS. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. Oncotarget 2017;8:47555-64. [PMID: 28548930 DOI: 10.18632/oncotarget.17733] [Reference Citation Analysis]
123 Quint K, Agaimy A, Di Fazio P, Montalbano R, Steindorf C, Jung R, Hellerbrand C, Hartmann A, Sitter H, Neureiter D. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch. 2011;459:129-139. [PMID: 21713366 DOI: 10.1007/s00428-011-1103-0)] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
124 Nagaoki Y, Aikata H, Miyaki D, Murakami E, Hashimoto Y, Katamura Y, Azakami T, Kawaoka T, Takaki S, Hiramatsu A. Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. J Gastroenterol. 2011;46:799-808. [PMID: 21373851 DOI: 10.1007/s00535-011-0384-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
125 Huang Y, Zeng J, Liu T, Lin X, Guo P, Zeng J, Zhou W, Liu J. Prognostic Significance of Elevated Preoperative Serum CA125 Levels After Curative Hepatectomy for Hepatocellular Carcinoma. Onco Targets Ther 2020;13:4559-67. [PMID: 32547086 DOI: 10.2147/OTT.S236475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
126 Kudo M. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer. 2015;4:39-50. [PMID: 26020028 DOI: 10.1159/000367727] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 11.7] [Reference Citation Analysis]
127 Perera S, Kelly D, O'Kane GM. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease. Curr Oncol 2020;27:S165-72. [PMID: 33343210 DOI: 10.3747/co.27.7159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
128 Massabeau C, Marchand V, Zefkili S, Servois V, Campana F, Giraud P. Early experience of helical tomotherapy for hepatobiliary radiotherapy. Case Reports Hepatol 2011;2011:545267. [PMID: 25954545 DOI: 10.1155/2011/545267] [Reference Citation Analysis]
129 Xie Y, Tian H, Xiang H. Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma? Tumori 2021;107:292-303. [PMID: 32729385 DOI: 10.1177/0300891620945029] [Reference Citation Analysis]
130 Samarakoon SR, Thabrew I, Galhena PB, De Silva D, Tennekoon KH. A comparison of the cytotoxic potential of standardized aqueous and ethanolic extracts of a polyherbal mixture comprised of Nigella sativa (seeds), Hemidesmus indicus (roots) and Smilax glabra (rhizome). Pharmacognosy Res 2010;2:335-42. [PMID: 21713135 DOI: 10.4103/0974-8490.75451] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
131 Tao R, Wang ZF, Qiu W, He YF, Yan WQ, Sun WY, Li HJ. Role of S100A3 in human hepatocellular carcinoma and the anticancer effect of sodium cantharidinate. Exp Ther Med 2017;13:2812-8. [PMID: 28588665 DOI: 10.3892/etm.2017.4294] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
132 Alunni-Fabbroni M, Weber S, Öcal O, Seidensticker M, Mayerle J, Malfertheiner P, Ricke J. Circulating Cell-Free DNA Combined to Magnetic Resonance Imaging for Early Detection of HCC in Patients with Liver Cirrhosis. Cancers (Basel) 2021;13:521. [PMID: 33572923 DOI: 10.3390/cancers13030521] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Sho T, Suda G, Ogawa K, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Meguro T, Saga A, Miyagishima T, Yokoo H, Kamiyama T, Taketomi A, Sakamoto N. Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting. JGH Open. 2020;4:54-60. [PMID: 32055698 DOI: 10.1002/jgh3.12209] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
134 Nassir F, Ibdah JA. Role of mitochondria in alcoholic liver disease. World J Gastroenterol 2014; 20(9): 2136-2142 [PMID: 24605012 DOI: 10.3748/wjg.v20.i9.2136] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 58] [Article Influence: 7.4] [Reference Citation Analysis]
135 Kono H, Fujii H, Furuya S, Hara M, Hirayama K, Akazawa Y, Nakata Y, Tsuchiya M, Hosomura N, Sun C. Macrophage colony-stimulating factor expressed in non-cancer tissues provides predictive powers for recurrence in hepatocellular carcinoma. World J Gastroenterol 2016; 22(39): 8779-8789 [PMID: 27818593 DOI: 10.3748/wjg.v22.i39.8779] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
136 Villanueva A, Savic R, Llovet JM. Lymphotoxins: new targets for hepatocellular carcinoma. Cancer Cell 2009;16:272-3. [PMID: 19800570 DOI: 10.1016/j.ccr.2009.09.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
137 Steinway SN, Dang H, You H, Rountree CB, Ding W. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma. PLoS One. 2015;10:e0128159. [PMID: 26000702 DOI: 10.1371/journal.pone.0128159] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
138 Chen M, Huang JD, Hu L, Zheng BJ, Chen L, Tsang SL, Guan XY. Transgenic CHD1L expression in mouse induces spontaneous tumors. PLoS One. 2009;4:e6727. [PMID: 19701453 DOI: 10.1371/journal.pone.0006727] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
139 Zhu AX, Duda DG, Sahani DV, Jain RK. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J. 2009;15:263-268. [PMID: 19672141 DOI: 10.1097/PPO.0b013e3181af5e35] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
140 Yin CQ, Yuan CH, Qu Z, Guan Q, Chen H, Wang FB. Liquid Biopsy of Hepatocellular Carcinoma: Circulating Tumor-Derived Biomarkers. Dis Markers. 2016;2016:1427849. [PMID: 27403030 DOI: 10.1155/2016/1427849] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
141 Shu QH, Ge YS, Xu GL, Ma JL, Jia WD, Yu JH, Zhang CH, Liu WB. Clinical significance of expression of CD68 and CD11c in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2015; 23(22): 3538-3547 [DOI: 10.11569/wcjd.v23.i22.3538] [Reference Citation Analysis]
142 Han TS, Ban HS, Hur K, Cho HS. The Epigenetic Regulation of HCC Metastasis. Int J Mol Sci 2018;19:E3978. [PMID: 30544763 DOI: 10.3390/ijms19123978] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
143 Xiang J, Xiang Y, Lin S, Xin D, Liu X, Weng L, Chen T, Zhang M. Anticancer effects of deproteinized asparagus polysaccharide on hepatocellular carcinoma in vitro and in vivo. Tumour Biol 2014;35:3517-24. [PMID: 24310501 DOI: 10.1007/s13277-013-1464-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
144 Yamashita T. Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy. Clin Drug Investig 2012;32 Suppl 2:15-23. [PMID: 22873624 DOI: 10.1007/BF03265493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
145 Anaparthy R, Talwalkar JA, Yin M, Roberts LR, Fidler JL, Ehman RL. Liver stiffness measurement by magnetic resonance elastography is not associated with developing hepatocellular carcinoma in subjects with compensated cirrhosis. Aliment Pharmacol Ther 2011;34:83-91. [PMID: 21535445 DOI: 10.1111/j.1365-2036.2011.04673.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
146 Wiggermann P, Sieron D, Brosche C, Brauer T, Scheer F, Platzek I, Wawrzynek W, Stroszczynski C. Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Med Sci Monit. 2011;17:CR189-CR195. [PMID: 21455104 DOI: 10.12659/msm.881714] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
147 Koral K, Haynes M, Bowen WC, Orr A, Mars W, Michalopoulos GK. Lymphocyte-Specific Protein-1 Controls Sorafenib Sensitivity and Hepatocellular Proliferation through Extracellular Signal-Regulated Kinase 1/2 Activation. Am J Pathol 2018;188:2074-86. [PMID: 30126548 DOI: 10.1016/j.ajpath.2018.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
148 Keng VW, Sia D, Sarver AL, Tschida BR, Fan D, Alsinet C, Solé M, Lee WL, Kuka TP, Moriarity BS. Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology. 2013;57:120-130. [PMID: 22899566 DOI: 10.1002/hep.26004] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
149 Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol 2013; 19(43): 7515-7530 [PMID: 24282343 DOI: 10.3748/wjg.v19.i43.7515] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 57] [Article Influence: 7.7] [Reference Citation Analysis]
150 Kusano H, Ogasawara S, Akiba J, Nakayama M, Ueda K, Yano H. Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo. Int J Oncol 2013;42:1897-903. [PMID: 23588838 DOI: 10.3892/ijo.2013.1904] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
151 Kim H, Rhim H, Choi D, Lim HK, Kim YS, Lee WJ, Joh JW. Recurrence and treatment pattern in long-term survivors with hepatocellular carcinoma: a comparison between radiofrequency ablation and surgery as a first-line treatment. World J Surg. 2010;34:1881-1886. [PMID: 20376449 DOI: 10.1007/s00268-010-0533-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
152 Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res. 2013;43:147-154. [PMID: 23145926 DOI: 10.1111/j.1872-034x.2012.01113.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 81] [Article Influence: 11.3] [Reference Citation Analysis]
153 Somma F, D'Angelo R, Serra N, Gatta G, Grassi R, Fiore F. Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)? PLoS One 2015;10:e0129573. [PMID: 26110810 DOI: 10.1371/journal.pone.0129573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
154 Athwal VS, Pritchett J, Martin K, Llewellyn J, Scott J, Harvey E, Zaitoun AM, Mullan AF, Zeef LAH, Friedman SL, Irving WL, Hanley NA, Guha IN, Piper Hanley K. SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis. Sci Rep 2018;8:17905. [PMID: 30559459 DOI: 10.1038/s41598-018-36037-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
155 Wang B, He J, Liu C, Chang LJ. An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine 2006;24:3477-89. [PMID: 16530303 DOI: 10.1016/j.vaccine.2006.02.025] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
156 Mauro E, Forner A. Barcelona Clinic Liver Cancer 2022 update: Linking prognosis prediction and evidence-based treatment recommendation with multidisciplinary clinical decision-making. Liver Int 2022;42:488-91. [PMID: 35194931 DOI: 10.1111/liv.15180] [Reference Citation Analysis]
157 Inokawa Y, Inaoka K, Sonohara F, Hayashi M, Kanda M, Nomoto S. Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. Oncol Lett 2016;12:3662-8. [PMID: 27900050 DOI: 10.3892/ol.2016.5141] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
158 Cauchy F, Fuks D, Belghiti J. HCC: current surgical treatment concepts. Langenbecks Arch Surg 2012;397:681-95. [DOI: 10.1007/s00423-012-0911-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
159 Tsuda Y, Fukui H, Asai A, Fukunishi S, Miyaji K, Fujiwara S, Teramura K, Fukuda A, Higuchi K. An immunosuppressive subtype of neutrophils identified in patients with hepatocellular carcinoma. J Clin Biochem Nutr 2012;51:204-12. [PMID: 23170048 DOI: 10.3164/jcbn.12-32] [Cited by in Crossref: 8] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
160 Zhang Y, Yan S, Chen J, Gan C, Chen D, Li Y, Wen J, Kremerskothen J, Chen S, Zhang J, Cao Y. WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma. J Cell Mol Med 2017;21:3718-29. [PMID: 28815883 DOI: 10.1111/jcmm.13281] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
161 Zhou B, Li Y, Deng Q, Wang H, Wang Y, Cai B, Han ZG. SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt. Mol Cell Biochem 2013;379:191-9. [PMID: 23644876 DOI: 10.1007/s11010-013-1641-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
162 Cappelli A, Sangro P, Mosconi C, Deppe I, Terzi E, Bilbao JI, Rodriguez-Fraile M, De Benedittis C, Ricke J, Golfieri R, Sangro B. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. Eur J Nucl Med Mol Imaging 2019;46:661-8. [PMID: 30209522 DOI: 10.1007/s00259-018-4152-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
163 Wei CY, Liu QL, Liao LF, Xu H, Tan XH. Effect of overexpression of wild-type p53 on POLD1 expression and malignant cell behavior in human hepatocellular carcinoma cell line SMMC-7721. Shijie Huaren Xiaohua Zazhi 2011; 19(23): 2443-2449 [DOI: 10.11569/wcjd.v19.i23.2443] [Reference Citation Analysis]
164 Wong YH, Tan HY, Kasbollah A, Abdullah BJJ, Yeong CH. Preparation and In Vitro Evaluation of Neutron-Activated, Theranostic Samarium-153-Labeled Microspheres for Transarterial Radioembolization of Hepatocellular Carcinoma and Liver Metastasis. Pharmaceutics 2019;11:E596. [PMID: 31718079 DOI: 10.3390/pharmaceutics11110596] [Reference Citation Analysis]
165 Zhou Z, Gong L, Wang X, Hu Z, Wu G, Tang X, Peng X, Tang S, Meng M, Feng H. The role of regulatory B cells in digestive system diseases. Inflamm Res 2017;66:303-9. [PMID: 27878329 DOI: 10.1007/s00011-016-1007-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
166 Tang H, Jin Y, Jin S, Tan Z, Peng Z, Kuang Y. Arsenite inhibits the function of CD133+ CD13+ liver cancer stem cells by reducing PML and Oct4 protein expression. Tumour Biol. 2016;37:14103-14115. [PMID: 27517564 DOI: 10.1007/s13277-016-5195-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
167 Cao P, Ma B, Sun D, Zhang W, Qiu J, Qin L, Xue X. hsa_circ_0003410 promotes hepatocellular carcinoma progression by increasing the ratio of M2/M1 macrophages through the miR-139-3p/CCL5 axis. Cancer Sci 2021. [PMID: 34890089 DOI: 10.1111/cas.15238] [Reference Citation Analysis]
168 Chen CS, Li FK, Guo CY, Xiao JC, Hu HT, Cheng HT, Zheng L, Zong DW, Ma JL, Jiang L, Li HL. Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Oncotarget 2016;7:7241-52. [PMID: 26769845 DOI: 10.18632/oncotarget.6892] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
169 Guo W, Chen S, Wu Z, Zhuang W, Yang J. Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Technol Cancer Res Treat 2020;19:1533033820965587. [PMID: 33089769 DOI: 10.1177/1533033820965587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
170 Huang RX, Duan YY, Hu JA. Fish intake and risk of liver cancer: a meta-analysis. PLoS One. 2015;10:e0096102. [PMID: 25615823 DOI: 10.1371/journal.pone.0096102] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
171 Chen Z, Sun M, Yuan Q, Niu M, Yao C, Hou J, Wang H, Wen L, Liu Y, Li Z, He Z. Generation of functional hepatocytes from human spermatogonial stem cells. Oncotarget 2016;7:8879-95. [PMID: 26840458 DOI: 10.18632/oncotarget.7092] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
172 Huang FY, Wong DK, Tsui VW, Seto WK, Mak LY, Cheung TT, Lai KK, Yuen MF. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma. BMC Cancer 2019;19:789. [PMID: 31395065 DOI: 10.1186/s12885-019-6002-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
173 Yang B, Zan RY, Wang SY, Li XL, Wei ML, Guo WH, You X, Li J, Liao ZY. Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials. World J Surg Oncol. 2015;13:96. [PMID: 25889181 DOI: 10.1186/s12957-015-0516-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
174 Kim BK, Kim DY, Han KH, Seong J. Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. PLoS One 2019;14:e0223678. [PMID: 31622424 DOI: 10.1371/journal.pone.0223678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
175 Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, Labow D, Llovet JM, Schwartz M, Mazzaferro V. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology 2013;57:1426-35. [PMID: 22576353 DOI: 10.1002/hep.25832] [Cited by in Crossref: 189] [Cited by in F6Publishing: 177] [Article Influence: 21.0] [Reference Citation Analysis]
176 Ou XH, Liao LF, Liu HG, Xu H. Significance of POLD1 expression in primary hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2011; 19(2): 151-155 [DOI: 10.11569/wcjd.v19.i2.151] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
177 Edeline J, Raoul JL, Vauleon E, Guillygomac’h A, Boudjema K, Boucher E. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: A retrospective study. World J Gastroenterol 2009; 15(6): 713-716 [PMID: 19222095 DOI: 10.3748/wjg.15.713] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
178 Bertrand J, Caillol F, Borentain P, Raoul JL, Heyries L, Bories E, Pesenti C, Ratone JP, Bernard JP, Gerolami R, Giovannini M. Percutaneous hepatic radiofrequency for hepatocellular carcinoma: results and outcome of 46 patients. Hepat Med 2015;7:21-7. [PMID: 26056497 DOI: 10.2147/HMER.S67940] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
179 Gómez-Rubio M, Moya-Valdés M, García J. Diagnostic laparoscopy and laparoscopic ultrasonography with local anesthesia in hepatocellular carcinoma. World J Gastroenterol 2005; 11(26): 4120-4123 [PMID: 15996044 DOI: 10.3748/wjg.v11.i26.4120] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
180 Norman GL, Gatselis NK, Shums Z, Liaskos C, Bogdanos DP, Koukoulis GK, Dalekos GN. Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. World J Hepatol 2015; 7(14): 1875-1883 [PMID: 26207169 DOI: 10.4254/wjh.v7.i14.1875] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
181 Pang Q, Bi JB, Wang ZX, Xu XS, Qu K, Miao RC, Chen W, Zhou YY, Liu C. Simple models based on gamma-glutamyl transpeptidase and platelets for predicting survival in hepatitis B-associated hepatocellular carcinoma. Onco Targets Ther 2016;9:2099-109. [PMID: 27110127 DOI: 10.2147/OTT.S101465] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
182 Shindoh J, Kaseb A, Vauthey JN. Surgical strategy for liver cancers in the era of effective chemotherapy. Liver Cancer 2013;2:47-54. [PMID: 24159596 DOI: 10.1159/000346222] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
183 Yang JQ, Pan GD, Chu GP, Liu Z, Liu Q, Xiao Y, Yuan L. Interferon-alpha restrains growth and invasive potential of hepatocellular carcinoma induced by hepatitis B virus X protein. World J Gastroenterol 2008; 14(36): 5564-5569 [PMID: 18810776 DOI: 10.3748/wjg.14.5564] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
184 Severi T, van Malenstein H, Verslype C, van Pelt JF. Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin 2010;31:1409-20. [PMID: 20953207 DOI: 10.1038/aps.2010.142] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 8.6] [Reference Citation Analysis]
185 Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepatol 2015; 7(12): 1708-1717 [PMID: 26140091 DOI: 10.4254/wjh.v7.i12.1708] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 7.7] [Reference Citation Analysis]
186 Rui R, Lou J, Zou L, Zhong R, Wang J, Xia D, Wang Q, Li H, Wu J, Lu X, Li C, Liu L, Xia J, Xu H. Excess body mass index and risk of liver cancer: a nonlinear dose-response meta-analysis of prospective studies. PLoS One. 2012;7:e44522. [PMID: 23028553 DOI: 10.1371/journal.pone.0044522] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
187 Robertson CL, Srivastava J, Rajasekaran D, Gredler R, Akiel MA, Jariwala N, Siddiq A, Emdad L, Fisher PB, Sarkar D. The role of AEG-1 in the development of liver cancer. Hepat Oncol 2015;2:303-12. [PMID: 26798451 DOI: 10.2217/hep.15.10] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
188 Zhang Z, Zhou Y, Yang J, Hu K, Huang Y. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. BMC Cancer 2019;19:511. [PMID: 31142283 DOI: 10.1186/s12885-019-5735-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
189 Velázquez KT, Enos RT, Carson MS, Cranford TL, Bader JE, Chatzistamou I, Singh UP, Nagarkatti PS, Nagarkatti M, Davis JM, Carson JA, Murphy EA. Weight loss following diet-induced obesity does not alter colon tumorigenesis in the AOM mouse model. Am J Physiol Gastrointest Liver Physiol 2016;311:G699-712. [PMID: 27609769 DOI: 10.1152/ajpgi.00207.2016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
190 Bouvier A, Ozenne V, Aubé C, Boursier J, Vullierme MP, Thouveny F, Farges O, Vilgrain V. Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. Eur Radiol 2011;21:1719-26. [PMID: 21479978 DOI: 10.1007/s00330-011-2118-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
191 Teng CF, Wu HC, Su IJ, Jeng LB. Hepatitis B Virus Pre-S Mutants as Biomarkers and Targets for the Development and Recurrence of Hepatocellular Carcinoma. Viruses 2020;12:E945. [PMID: 32859114 DOI: 10.3390/v12090945] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
192 Sharma BK, Srinivasan R, Kapil S, Singla B, Saini N, Chawla YK, Chakraborti A, Duseja A, Kalra N, Dhiman RK. Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma. Mol Cell Biochem 2013;383:103-12. [PMID: 23912396 DOI: 10.1007/s11010-013-1759-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
193 Lin MT, Wang CC, Cheng YF, Eng HL, Yen YH, Tsai MC, Tseng PL, Chang KC, Wu CK, Hu TH. Comprehensive Comparison of Multiple-Detector Computed Tomography and Dynamic Magnetic Resonance Imaging in the Diagnosis of Hepatocellular Carcinoma with Varying Degrees of Fibrosis. PLoS One 2016;11:e0166157. [PMID: 27829060 DOI: 10.1371/journal.pone.0166157] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
194 Muscari F, Guinard JP, Kamar N, Peron JM, Otal P, Suc B. Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma. World J Surg. 2012;36:1824-1831. [PMID: 22532309 DOI: 10.1007/s00268-012-1587-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
195 Jia JB, Zhuang PY, Sun HC, Zhang JB, Zhang W, Zhu XD, Xiong YQ, Xu HX, Tang ZY. Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival. J Cancer Res Clin Oncol. 2009;135:847-854. [PMID: 19066962 DOI: 10.1007/s00432-008-0521-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
196 Fujita N, Nishie A, Kubo Y, Asayama Y, Ushijima Y, Takayama Y, Moirta K, Shirabe K, Aishima S, Honda H. Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging. Eur Radiol. 2015;25:211-220. [PMID: 25063395 DOI: 10.1007/s00330-014-3349-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
197 Shindoh J, Hashimoto M, Watanabe G. Surgical approach for hepatitis C virus-related hepatocellular carcinoma. World J Hepatol 2015; 7(1): 70-77 [PMID: 25624998 DOI: 10.4254/wjh.v7.i1.70] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
198 Li-Shuai Q, Yu-Yan C, Hai-Feng Z, Jin-Xia L, Cui-Hua L. Pre-S deletions of hepatitis B virus predict recurrence of hepatocellular carcinoma after curative resection. Medicine (Baltimore) 2017;96:e8311. [PMID: 29069001 DOI: 10.1097/MD.0000000000008311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
199 Wu X, Li C, Xing G, Qi X, Ren J. Resveratrol Downregulates Cyp2e1 and Attenuates Chemically Induced Hepatocarcinogenesis in SD Rats. J Toxicol Pathol 2013;26:385-92. [PMID: 24526811 DOI: 10.1293/tox.2013-0020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
200 Park JO, Ryoo BY, Yen CJ, Kudo M, Yang L, Abada PB, Cheng R, Orlando M, Zhu AX, Okusaka T. Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. Oncotarget. 2016;7:75482-75491. [PMID: 27776351 DOI: 10.18632/oncotarget.12780] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
201 Ma BY, Li J, Lu Q, Yan LN, Luo Y, Peng YL. Prognostic value of portal vein involvement in patients undergoing liver transplantation for hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2010; 18(5): 512-516 [DOI: 10.11569/wcjd.v18.i5.512] [Reference Citation Analysis]
202 Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, Cornella H, Llovet JM. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010;16:4688-94. [PMID: 20713493 DOI: 10.1158/1078-0432.CCR-09-1811] [Cited by in Crossref: 92] [Cited by in F6Publishing: 59] [Article Influence: 7.7] [Reference Citation Analysis]
203 Xie Q, Liu H, Guo Z, Wu Y, He G, Cai L, Pan M, Fu S. Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy. Front Mol Biosci 2022;8:810251. [DOI: 10.3389/fmolb.2021.810251] [Reference Citation Analysis]
204 Tokuhisa Y, Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Sakamoto K, Tamesa T, Oka M. Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer 2007;97:1399-403. [PMID: 17940509 DOI: 10.1038/sj.bjc.6604034] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 3.6] [Reference Citation Analysis]
205 Zhong C, Guo RP, Li JQ, Shi M, Wei W, Chen MS, Zhang YQ. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135:1437-1445. [PMID: 19408012 DOI: 10.1007/s00432-009-0588-2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 5.6] [Reference Citation Analysis]
206 Sui CJ, Zhou YM, Shen WF, Dai BH, Lu JJ, Zhang MF, Yang JM. Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429. J Mol Med (Berl). 2016;94:1281-1296. [PMID: 27380494 DOI: 10.1007/s00109-016-1442-z] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 9.2] [Reference Citation Analysis]
207 Chang YS, Lee YT, Yen JC, Chang YC, Lin LL, Chan WL, Chang WC, Lin SY, Chang JG. Long Noncoding RNA NTT Context-Dependently Regulates MYB by Interacting With Activated Complex in Hepatocellular Carcinoma Cells. Front Oncol 2021;11:592045. [PMID: 34616668 DOI: 10.3389/fonc.2021.592045] [Reference Citation Analysis]
208 Ruan Y, Sun L, Hao Y, Wang L, Xu J, Zhang W, Xie J, Guo L, Zhou L, Yun X, Zhu H, Shen A, Gu J. Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma. J Clin Invest 2012;122:2554-66. [PMID: 22653060 DOI: 10.1172/JCI58488] [Cited by in Crossref: 83] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
209 Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91. [PMID: 19224838 DOI: 10.1200/JCO.2008.20.7753] [Cited by in Crossref: 1121] [Cited by in F6Publishing: 613] [Article Influence: 86.2] [Reference Citation Analysis]
210 Teng CF, Li TC, Huang HY, Chan WL, Wu HC, Shyu WC, Su IJ, Jeng LB. Hepatitis B virus pre-S2 deletion (nucleotide 1 to 54) in plasma predicts recurrence of hepatocellular carcinoma after curative surgical resection. PLoS One 2020;15:e0242748. [PMID: 33237972 DOI: 10.1371/journal.pone.0242748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
211 Liang S, Lin X, Liang Y, Song D, Zhang L, Fan X. Killing Effects of IFN R-/- Mouse NK Cells Activated by HN Protein of NDV on Mouse Hepatoma Cells and Possible Mechanism with Syk and NF-κB. Anat Rec (Hoboken) 2019;302:1718-25. [PMID: 31120191 DOI: 10.1002/ar.24177] [Reference Citation Analysis]
212 Topal H, Tiek J, Fieuws S, Pirenne J, Nevens F, Topal B. The impact of liver transplantation after surgical treatment of hepatocellular carcinoma. Front Surg 2014;1:29. [PMID: 25593953 DOI: 10.3389/fsurg.2014.00029] [Reference Citation Analysis]
213 Liu X, Zhu L, Ma J, Qiao X, Zhu D, Liu L, Leng X. Target-specific delivery of siRNA into hepatoma cells' cytoplasm by bifunctional carrier peptide. Drug Deliv Transl Res 2017;7:147-55. [PMID: 27896668 DOI: 10.1007/s13346-016-0348-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
214 Kaneko S, Ikeda K, Matsuzaki Y, Furuse J, Minami H, Okayama Y, Sunaya T, Ito Y, Inuyama L, Okita K. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. J Gastroenterol 2016;51:1011-21. [PMID: 26931117 DOI: 10.1007/s00535-016-1173-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
215 Zhai G, Yang H, Ji X, Xiong F, Su J, McNutt MA, Li X. Correlation of LAPTM4B polymorphisms with hepatocellular carcinoma in Chinese patients. Med Oncol 2012;29:2744-9. [PMID: 22207410 DOI: 10.1007/s12032-011-0139-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
216 Avella DM, Kimchi ET, Donahue RN, Tagaram HR, McLaughlin PJ, Zagon IS, Staveley-O'Carroll KF. The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer. Am J Physiol Regul Integr Comp Physiol 2010;298:R459-66. [PMID: 19923357 DOI: 10.1152/ajpregu.00646.2009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
217 Mustafa GM, Larry D, Petersen JR, Elferink CJ. Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients. World J Hepatol 2015; 7(10): 1312-1324 [PMID: 26052377 DOI: 10.4254/wjh.v7.i10.1312] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
218 Gedaly R, Galuppo R, Daily MF, Shah M, Maynard E, Chen C, Zhang X, Esser KA, Cohen DA, Evers BM. Targeting the Wnt/β-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535. PLoS One. 2014;9:e99272. [PMID: 24940873 DOI: 10.1371/journal.pone.0099272] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 8.5] [Reference Citation Analysis]
219 Sukowati CH, Rosso N, Crocè LS, Tiribelli C. Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. World J Hepatol 2010; 2(3): 114-126 [PMID: 21160982 DOI: 10.4254/wjh.v2.i3.114] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
220 Dong C, Zhao B, Long F, Liu Y, Liu Z, Li S, Yang X, Sun D, Wang H, Liu Q, Liang R, Li Y, Gao Z, Shao S, Miao QR, Wang L. Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein. Oncotarget 2016;7:8850-65. [PMID: 26840457 DOI: 10.18632/oncotarget.7091] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
221 Ueshima K, Kudo M, Tanaka M, Kumada T, Chung H, Hagiwara S, Inoue T, Yada N, Kitai S. Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-Fluorouracil. Liver Cancer 2015;4:263-73. [PMID: 26734580 DOI: 10.1159/000367751] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
222 Xie C, Song LB, Wu JH, Li J, Yun JP, Lai JM, Xie DY, Lin BL, Yuan YF, Li M. Upregulator of cell proliferation predicts poor prognosis in hepatocellular carcinoma and contributes to hepatocarcinogenesis by downregulating FOXO3a. PLoS One. 2012;7:e40607. [PMID: 22815774 DOI: 10.1371/journal.pone.0040607] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
223 Xue H, Lin F, Tan H, Zhu ZQ, Zhang ZY, Zhao L. Overrepresentation of IL-10-Expressing B Cells Suppresses Cytotoxic CD4+ T Cell Activity in HBV-Induced Hepatocellular Carcinoma. PLoS One 2016;11:e0154815. [PMID: 27136203 DOI: 10.1371/journal.pone.0154815] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
224 Cherqui D, Laurent A, Tayar C, Chang S, Van Nhieu JT, Loriau J, Karoui M, Duvoux C, Dhumeaux D, Fagniez PL. Laparoscopic liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: midterm results and perspectives. Ann Surg 2006;243:499-506. [PMID: 16552201 DOI: 10.1097/01.sla.0000206017.29651.99] [Cited by in Crossref: 229] [Cited by in F6Publishing: 211] [Article Influence: 14.3] [Reference Citation Analysis]
225 Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, Yang J. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol. 2010;10:78. [PMID: 20618937 DOI: 10.1186/1471-230x-10-78] [Cited by in Crossref: 116] [Cited by in F6Publishing: 60] [Article Influence: 9.7] [Reference Citation Analysis]
226 Wang R, Geller DA, Wink DA, Cheng B, Billiar TR. NO and hepatocellular cancer. Br J Pharmacol 2020;177:5459-66. [PMID: 31423564 DOI: 10.1111/bph.14838] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
227 Nel I, Baba HA, Ertle J, Weber F, Sitek B, Eisenacher M, Meyer HE, Schlaak JF, Hoffmann AC. Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma. Transl Oncol 2013;6:420-8. [PMID: 23908685 DOI: 10.1593/tlo.13271] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
228 Koya Y, Suzuki T, Tai M, Ichii O, Matsuhashi N, Ejiri Y, Shibata M, Harada M. Spontaneous Regression of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Case Rep Gastroenterol 2018;12:411-9. [PMID: 30186093 DOI: 10.1159/000490661] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
229 Walker M, El-Serag HB, Sada Y, Mittal S, Ying J, Duan Z, Richardson P, Davila JA, Kanwal F. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther 2016;43:621-30. [PMID: 26784271 DOI: 10.1111/apt.13505] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 6.5] [Reference Citation Analysis]
230 Wang Z, Li X, Chen J, Shi H, Pan J, Zhang X, Jin Z. Safety and effectiveness of repeat arterial closure using the StarClose vascular closure device in patients with hepatic malignancy. Clin Radiol 2013;68:e498-501. [PMID: 23706825 DOI: 10.1016/j.crad.2013.04.001] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
231 Al-Dali AM, Weiher H, Schmidt-Wolf IGH. Utilizing ethacrynic acid and ciclopirox olamine in liver cancer. Oncol Lett 2018;16:6854-60. [PMID: 30405829 DOI: 10.3892/ol.2018.9472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
232 Chen RX, Xia YH, Xue TC, Ye SL. Transcription factor c-Myb promotes the invasion of hepatocellular carcinoma cells via increasing osteopontin expression. J Exp Clin Cancer Res 2010;29:172. [PMID: 21190594 DOI: 10.1186/1756-9966-29-172] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
233 Zhang R, Lin HM, Broering R, Shi XD, Yu XH, Xu LB, Wu WR, Liu C. Dickkopf-1 contributes to hepatocellular carcinoma tumorigenesis by activating the Wnt/β-catenin signaling pathway. Signal Transduct Target Ther 2019;4:54. [PMID: 31839998 DOI: 10.1038/s41392-019-0082-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
234 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
235 Wang C, Gao W, Feng M, Pastan I, Ho M. Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy. Oncotarget 2017;8:32450-60. [PMID: 27419635 DOI: 10.18632/oncotarget.10592] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
236 Kim TM, Yim SH, Shin SH, Xu HD, Jung YC, Park CK, Choi JY, Park WS, Kwon MS, Fiegler H, Carter NP, Rhyu MG, Chung YJ. Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int J Cancer. 2008;123:2808-2815. [PMID: 18803288 DOI: 10.1002/ijc.23901] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.0] [Reference Citation Analysis]
237 Guan TP, Fang CH, Yang J, Xiang N, Chen QS, Zhong SZ. A Comparison between Three-Dimensional Visualization Guided Hepatectomy and Ultrasonography Guided Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinoma within the Milan Criteria. Biomed Res Int 2016;2016:8931732. [PMID: 27294142 DOI: 10.1155/2016/8931732] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
238 Dong C, Liu Y, Jiang K, Wang H, Qu W, Zhang C, Liang R, Gao Z, Zhao B, Miao Q, Shao S, Wang L. The Nogo-B receptor promotes human hepatocellular carcinoma cell growth via the Akt signal pathway. J Cell Biochem 2018;119:7738-46. [PMID: 29904947 DOI: 10.1002/jcb.27125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
239 Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, Kerbel RS, Sata M. Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol 2013;6:511-9. [PMID: 24151531 DOI: 10.1593/tlo.13481] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
240 Oh MJ, Lee HJ, Lee SH. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy. Clin Mol Hepatol. 2013;19:288-299. [PMID: 24133667 DOI: 10.3350/cmh.2013.19.3.288] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
241 Turato C, Vitale A, Fasolato S, Ruvoletto M, Terrin L, Quarta S, Ramirez Morales R, Biasiolo A, Zanus G, Zali N. SERPINB3 is associated with TGF-β1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis. Br J Cancer. 2014;110:2708-2715. [PMID: 24809782 DOI: 10.1038/bjc.2014.246] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
242 Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol. 2008;20:444-453. [PMID: 18525342 DOI: 10.1097/CCO.0b013e328302c9e9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
243 Wang K, Bai Y, Chen S, Huang J, Yuan J, Chen W, Yao P, Miao X, Wang Y, Liang Y, Zhang X, He M, Yang H, Guo H, Wei S. Genetic correction of serum AFP level improves risk prediction of primary hepatocellular carcinoma in the Dongfeng-Tongji cohort study. Cancer Med 2018;7:2691-8. [PMID: 29696820 DOI: 10.1002/cam4.1481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
244 Miraglia R, Pietrosi G, Maruzzelli L, Petridis I, Caruso S, Marrone G, Mamone G, Vizzini G, Luca A, Gridelli B. Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma. World J Gastroenterol 2007; 13(21): 2952-2955 [PMID: 17589945 DOI: 10.3748/wjg.v13.i21.2952] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 43] [Article Influence: 2.5] [Reference Citation Analysis]
245 Zhang YC, Wang XP, Zhang LY, Song AL, Kou ZM, Li XS. Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells. World J Gastroenterol 2006; 12(25): 3977-3982 [PMID: 16810743 DOI: 10.3748/wjg.v12.i25.3977] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
246 Li Y, Xu Y, Wang R, Li W, He W, Luo X, Ye Y. Expression of Notch-Hif-1α signaling pathway in liver regeneration of rats. J Int Med Res 2020;48:300060520943790. [PMID: 32967512 DOI: 10.1177/0300060520943790] [Reference Citation Analysis]
247 Qu JH, Chang XJ, Lu YY, Bai WL, Chen Y, Zhou L, Zeng Z, Wang CP, An LJ, Hao LY, Xu GL, Gao XD, Lou M, Lv JY, Yang YP. Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2012; 18(23): 2995-3003 [PMID: 22736924 DOI: 10.3748/wjg.v18.i23.2995] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
248 Wembulua BS, Diallo K, Thioubou MA, Nguma JDB, Manga NM. Hepatitis B-related hepatocellular carcinoma in a 36-year-old pregnant woman: prognosis and management dilemma. Pan Afr Med J 2020;36:298. [PMID: 33117492 DOI: 10.11604/pamj.2020.36.298.22658] [Reference Citation Analysis]
249 Pradhan-Sundd T, Monga SP. Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology. Gene Expr 2019;19:69-87. [PMID: 30646969 DOI: 10.3727/105221619X15469715711907] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
250 Chai Z, Yin X, Chen J, Shi J, Sun J, Liu C, Liu F, Cheng S. MicroRNA-101 modulates cisplatin chemoresistance in liver cancer cells via the DNA-PKcs signaling pathway. Oncol Lett 2019;18:3655-63. [PMID: 31516578 DOI: 10.3892/ol.2019.10674] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
251 Zhang L, Wang N, Shen Q, Cheng W, Qian GJ. Therapeutic efficacy of percutaneous radiofrequency ablation versus microwave ablation for hepatocellular carcinoma. PLoS One. 2013;8:e76119. [PMID: 24146824 DOI: 10.1371/journal.pone.0076119] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 7.1] [Reference Citation Analysis]
252 Kasuya G, Kato H, Yasuda S, Tsuji H, Yamada S, Haruyama Y, Kobashi G, Ebner DK, Okada NN, Makishima H, Miyazaki M, Kamada T, Tsujii H; Liver Cancer Working Group. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials. Cancer 2017;123:3955-65. [PMID: 28662297 DOI: 10.1002/cncr.30816] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 7.2] [Reference Citation Analysis]
253 Wang XP, Mao MJ, He ZL, Zhang L, Chi PD, Su JR, Dai SQ, Liu WL. A retrospective discussion of the prognostic value of combining prothrombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma. J Cancer 2017;8:2079-87. [PMID: 28819409 DOI: 10.7150/jca.19181] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
254 Frost K, Seir K, Lackner A, Grusch M, Grasl-Kraupp B, Schulte-Hermann R, Rodgarkia-Dara C. Inhibin/activin expression in human and rodent liver: subunits α and βB as new players in human hepatocellular carcinoma? Br J Cancer 2011;104:1303-12. [PMID: 21407220 DOI: 10.1038/bjc.2011.53] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
255 Pecenka V, Pajer P, Karafiat V, Kasparova P, Dudlova J, Dvorak M. HRAS, EGFR, MET, and RON Genes Are Recurrently Activated by Provirus Insertion in Liver Tumors Induced by the Retrovirus Myeloblastosis-Associated Virus 2. J Virol 2017;91:e00467-17. [PMID: 28768863 DOI: 10.1128/JVI.00467-17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
256 Zhu Q, Qiao GL, Xu C, Guo DL, Tang J, Duan R, Li Y. Partial hepatectomy for spontaneous tumor rupture in patients with hepatocellular carcinoma: a retrospective cohort study. Cancer Manag Res 2017;9:525-37. [PMID: 29089785 DOI: 10.2147/CMAR.S146708] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
257 Matsumoto T, Kubota K, Aoki T, Iso Y, Kato M, Shimoda M. Clinical Impact of Anatomical Liver Resection for Hepatocellular Carcinoma with Pathologically Proven Portal Vein Invasion. World J Surg 2016;40:402-11. [PMID: 26306893 DOI: 10.1007/s00268-015-3231-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
258 Shiina S. Image-guided percutaneous ablation therapies for hepatocellular carcinoma. J Gastroenterol 2009;44:122-31. [DOI: 10.1007/s00535-008-2263-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
259 Santhekadur PK, Akiel M, Emdad L, Gredler R, Srivastava J, Rajasekaran D, Robertson CL, Mukhopadhyay ND, Fisher PB, Sarkar D. Staphylococcal nuclease domain containing-1 (SND1) promotes migration and invasion via angiotensin II type 1 receptor (AT1R) and TGFβ signaling. FEBS Open Bio 2014;4:353-61. [PMID: 24918049 DOI: 10.1016/j.fob.2014.03.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
260 Kim JY, Lee HY, Park KK, Choi YK, Nam JS, Hong IS. CWP232228 targets liver cancer stem cells through Wnt/β-catenin signaling: a novel therapeutic approach for liver cancer treatment. Oncotarget. 2016;7:20395-20409. [PMID: 26967248 DOI: 10.18632/oncotarget.7954] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 8.3] [Reference Citation Analysis]
261 Dugum M, Hanouneh I, McIntyre T, Pai R, Aucejo F, Eghtesad B, Zein N. Sonic hedgehog signaling in hepatocellular carcinoma: A pilot study. Mol Clin Oncol. 2016;4:369-374. [PMID: 26998285 DOI: 10.3892/mco.2016.728] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
262 Kamo N, Kaido T, Yagi S, Okajima H, Uemoto S. Liver Transplantation for Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer 2018;7:179-89. [PMID: 29888207 DOI: 10.1159/000487058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
263 Ding M, Wang Y, Chi J, Wang T, Tang X, Cui D, Qian Q, Zhai B. Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients. PLoS One. 2016;11:e0168798. [PMID: 28006010 DOI: 10.1371/journal.pone.0168798] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
264 Plentz RR, Malek NP. Early Detection of Hepatocellular Carcinoma: How to Screen and Follow up Patients with Liver Cirrhosis According to the GERMAN S3 Guideline? Diagnostics (Basel) 2015;5:497-503. [PMID: 26854167 DOI: 10.3390/diagnostics5040497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
265 Martin M, Herceg Z. From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms. Genome Med. 2012;4:8. [PMID: 22293089 DOI: 10.1186/gm307] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
266 Bour G, Martel F, Goffin L, Bayle B, Gangloff J, Aprahamian M, Marescaux J, Egly JM. Design and development of a robotized system coupled to µCT imaging for intratumoral drug evaluation in a HCC mouse model. PLoS One 2014;9:e106675. [PMID: 25203629 DOI: 10.1371/journal.pone.0106675] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
267 Gu Y, Yang X, Liang H, Li D. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol 2019;19:231. [PMID: 31888534 DOI: 10.1186/s12876-019-1147-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
268 Hutt DM, Roth DM, Vignaud H, Cullin C, Bouchecareilh M. The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition. PLoS One. 2014;9:e106224. [PMID: 25166596 DOI: 10.1371/journal.pone.0106224] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
269 Lee JH, Kim HG, Oh JH, Lee YJ. Dramatic increase in hepatic and biliary curcumin exposure by modulation of its elimination pathway in rats. J Pharm Pharmacol 2013;65:423-9. [PMID: 23356851 DOI: 10.1111/j.2042-7158.2012.01610.x] [Reference Citation Analysis]
270 Liu Y, Liu H, Yang L, Wu Q, Liu W, Fu Q, Zhang W, Zhang H, Xu J, Gu J. Loss of N-Acetylgalactosaminyltransferase-4 Orchestrates Oncogenic MicroRNA-9 in Hepatocellular Carcinoma. J Biol Chem 2017;292:3186-200. [PMID: 28062574 DOI: 10.1074/jbc.M116.751685] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
271 Huang C, Zhu XD, Shen YH, Wu D, Ji Y, Ge NL, Chen LL, Tan CJ, Zhou J, Fan J, Sun HC. Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. Biomark Res 2021;9:19. [PMID: 33743822 DOI: 10.1186/s40364-021-00274-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
272 Zhou P, Liang P, Yu X, Wang Y, Dong B. Percutaneous microwave ablation of liver cancer adjacent to the gastrointestinal tract. J Gastrointest Surg. 2009;13:318-324. [PMID: 18825464 DOI: 10.1007/s11605-008-0710-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
273 Song DS, Choi JY, Yoo SH, Kim HY, Song MJ, Bae SH, Yoon SK, Chun HJ, Choi BG, Lee HG. DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarteral Chemoembolization: A Pilot Study. Gut Liver 2013;7:89-95. [PMID: 23424047 DOI: 10.5009/gnl.2013.7.1.89] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
274 Karabulut K, Aucejo F, Akyildiz HY, Siperstein A, Berber E. Resection and radiofrequency ablation in the treatment of hepatocellular carcinoma: a single-center experience. Surg Endosc. 2012;26:990-997. [PMID: 22038164 DOI: 10.1007/s00464-011-1983-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
275 Dai XM, Huang T, Yang SL, Zheng XM, Chen GG, Zhang T. Peritumoral EpCAM Is an Independent Prognostic Marker after Curative Resection of HBV-Related Hepatocellular Carcinoma. Dis Markers 2017;2017:8495326. [PMID: 28572700 DOI: 10.1155/2017/8495326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
276 Xiang ZL, Zeng ZC, Tang ZY, Fan J, Sun HC, Tan YS. Expression of cytokeratin 19 and matrix metalloproteinase 2 predicts lymph node metastasis in hepatocellular carcinoma. Mol Biol Rep. 2011;38:3531-3539. [PMID: 21104440 DOI: 10.1007/s11033-010-0463-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
277 Pei T, Meng Q, Han J, Sun H, Li L, Song R, Sun B, Pan S, Liang D, Liu L. (-)-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma. Oncotarget 2016;7:43475-91. [PMID: 27259268 DOI: 10.18632/oncotarget.9782] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
278 Jiang Y, Yim SH, Xu HD, Jung SH, Yang SY, Hu HJ, Jung CK, Chung YJ. A potential oncogenic role of the commonly observed E2F5 overexpression in hepatocellular carcinoma. World J Gastroenterol 2011; 17(4): 470-477 [PMID: 21274376 DOI: 10.3748/wjg.v17.i4.470] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
279 Ai N, Liu W, Li ZG, Ji H, Li B, Yang G. High expression of GP73 in primary hepatocellular carcinoma and its function in the assessment of transcatheter arterial chemoembolization. Oncol Lett. 2017;14:3953-3958. [PMID: 28943903 DOI: 10.3892/ol.2017.6697] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
280 Qi X, Schepers E, Avella D, Kimchi ET, Kaifi JT, Staveley-O'Carroll KF, Li G. An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis. J Vis Exp 2019. [PMID: 31566616 DOI: 10.3791/59368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
281 Lu H, Li X, Zhang J, Shi H, Zhu X, He X. Effects of cordycepin on HepG2 and EA.hy926 cells: Potential antiproliferative, antimetastatic and anti-angiogenic effects on hepatocellular carcinoma. Oncol Lett 2014;7:1556-62. [PMID: 24765175 DOI: 10.3892/ol.2014.1965] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
282 Wang C, Lu Y, Wang H, Gao X, Bai W, Qu J, Xu G, Zhang Z, Zeng Z, Zhou L, An L, Lv J, Yang Y. Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med 2012;4:188-96. [PMID: 23139708 DOI: 10.3892/etm.2012.569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
283 Liu M, Du L, He Z, Yan L, Shi Y, Shang J, Tang H. Increased ERp57 Expression in HBV-Related Hepatocellular Carcinoma: Possible Correlation and Prognosis. Biomed Res Int 2017;2017:1252647. [PMID: 28373975 DOI: 10.1155/2017/1252647] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
284 Liu W, Kang L, Han J, Wang Y, Shen C, Yan Z, Tai Y, Zhao C. miR-342-3p suppresses hepatocellular carcinoma proliferation through inhibition of IGF-1R-mediated Warburg effect. Onco Targets Ther 2018;11:1643-53. [PMID: 29615839 DOI: 10.2147/OTT.S161586] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
285 Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312-1327. [PMID: 18821591 DOI: 10.1002/hep.22506] [Cited by in Crossref: 747] [Cited by in F6Publishing: 709] [Article Influence: 53.4] [Reference Citation Analysis]
286 Wang H, Jiang F, Hao F, Ju R. The expression of HtrA2 and its diagnostic value in patients with hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e0128. [PMID: 29620624 DOI: 10.1097/MD.0000000000010128] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
287 Kudou M, Shiozaki A, Kosuga T, Ichikawa D, Konishi H, Morimura R, Komatsu S, Ikoma H, Fujiwara H, Okamoto K, Hosogi S, Nakahari T, Marunaka Y, Otsuji E. Inhibition of Regulatory Volume Decrease Enhances the Cytocidal Effect of Hypotonic Shock in Hepatocellular Carcinoma. J Cancer 2016;7:1524-33. [PMID: 27471568 DOI: 10.7150/jca.15181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
288 Kim JS, Choi GH, Jung Y, Kim KM, Jang SJ, Yu ES, Lee HC. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines. J Cancer Res Clin Oncol 2018;144:1487-501. [PMID: 29858683 DOI: 10.1007/s00432-018-2672-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
289 Pang TC, Lam VW. Surgical management of hepatocellular carcinoma. World J Hepatol 2015; 7(2): 245-252 [PMID: 25729479 DOI: 10.4254/wjh.v7.i2.245] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
290 Ofosu A, Gurakar A. Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update. Euroasian J Hepatogastroenterol 2015;5:19-25. [PMID: 29201680 DOI: 10.5005/jp-journals-10018-1123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
291 Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, Weber A, Slankamenac K, Poon RT, Yang H, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut. 2012;61:427-438. [PMID: 21930732 DOI: 10.1136/gutjnl-2011-300509] [Cited by in Crossref: 192] [Cited by in F6Publishing: 184] [Article Influence: 17.5] [Reference Citation Analysis]
292 Tang H, Lu W, Yang Z, Jiang K, Chen Y, Lu S, Dong J. Risk factors and long-term outcome for postoperative intra-abdominal infection after hepatectomy for hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e6795. [PMID: 28445320 DOI: 10.1097/MD.0000000000006795] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
293 Mazzoccoli G, Tarquini R, Valoriani A, Oben J, Vinciguerra M, Marra F. Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med 2016;16:243-56. [PMID: 26077653 DOI: 10.1007/s10238-015-0368-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
294 Saito T, Chiba T, Suzuki E, Shinozaki M, Goto N, Kanogawa N, Motoyama T, Ogasawara S, Ooka Y, Tawada A. Effect of previous interferon-based therapy on recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Med Sci. 2014;11:707-712. [PMID: 24843320 DOI: 10.7150/ijms.8764] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
295 Swe T, Naing AT, Baqui A, Khillan R. Severe Anemia with Hemoperitoneum as a First Presentation for Multinodular Hepatocellular Carcinoma: A Rare Event in Western Countries. Case Reports Hepatol 2016;2016:7082387. [PMID: 27999693 DOI: 10.1155/2016/7082387] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
296 Chen L, Tian H, Li M, Ge C, Zhao F, Zhang L, Li H, Liu J, Wang T, Yao M, Li J. Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis. Tumour Biol 2016;37:5951-61. [PMID: 26596832 DOI: 10.1007/s13277-015-4362-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
297 Petersen J, Henninger B, Glodny B, Jaschke W. [Transarterial chemoembolisation in hepatocellular carcinoma]. Wien Med Wochenschr 2013;163:123-7. [PMID: 23413009 DOI: 10.1007/s10354-013-0180-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
298 Kudo M. New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma. Int J Clin Oncol. [DOI: 10.1007/s10147-022-02166-0] [Reference Citation Analysis]
299 Kudo M, Ikeda M, Takayama T, Numata K, Izumi N, Furuse J, Okusaka T, Kadoya M, Yamashita S, Ito Y, Kokudo N. Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. J Gastroenterol 2016;51:1150-60. [PMID: 27106231 DOI: 10.1007/s00535-016-1204-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
300 Coleman SJ, Grose RP, Kocher HM. Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:43-54. [PMID: 27508175 DOI: 10.2147/JHC.S48958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
301 Salgia R, Mendiratta V. The Multidisciplinary Management of Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2021;17:405-8. [PMID: 34386204 DOI: 10.1002/cld.1068] [Reference Citation Analysis]
302 Qian WP, Tan YQ, Chen Y, Peng Y, Li Z, Lu GX, Lin MC, Kung HF, He ML, Shing LK. Rapid quantification of semen hepatitis B virus DNA by real-time polymerase chain reaction. World J Gastroenterol 2005; 11(34): 5385-5389 [PMID: 16149152 DOI: 10.3748/wjg.v11.i34.5385] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
303 Shindoh J, Kawamura Y, Kobayashi Y, Akuta N, Kobayashi M, Suzuki Y, Ikeda K, Hashimoto M. Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes after Resection of Hepatocellular Carcinoma. J Gastrointest Surg 2020;24:50-7. [PMID: 31190124 DOI: 10.1007/s11605-019-04277-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
304 Mikoshiba N, Tateishi R, Tanaka M, Sakai T, Blazeby JM, Kokudo N, Koike K, Kazuma K. Validation of the Japanese version of the EORTC hepatocellular carcinoma-specific quality of life questionnaire module (QLQ-HCC18). Health Qual Life Outcomes 2012;10:58. [PMID: 22651810 DOI: 10.1186/1477-7525-10-58] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
305 Hucke F, Sieghart W, Schöniger-Hekele M, Peck-Radosavljevic M, Müller C. Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? Wien Klin Wochenschr. 2011;123:542-551. [PMID: 21800047 DOI: 10.1007/s00508-011-0033-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
306 Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KPS, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. OncoTargets and therapy. 2016;773-780. [PMID: 26929648 DOI: 10.2147/ott.s91977] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
307 Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2021:S0168-8278(21)02223-6. [PMID: 34801630 DOI: 10.1016/j.jhep.2021.11.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
308 Perumpail RB, Wong RJ, Ahmed A, Harrison SA. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Dig Dis Sci. 2015;60:3142-3148. [PMID: 26250831 DOI: 10.1007/s10620-015-3821-7] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 9.0] [Reference Citation Analysis]
309 Lee SD, Kim SH, Kim YK, Lee SA, Park SJ. Prognostic significance of preoperative peripheral blood monocyte ratio in patients with hepatocellular carcinoma. World J Surg. 2014;38:2377-2385. [PMID: 24692003 DOI: 10.1007/s00268-014-2545-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
310 Varshosaz J, Farzan M. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12022-12041 [PMID: 26576089 DOI: 10.3748/wjg.v21.i42.12022] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
311 Honda M, Yamashita T, Yamashita T, Arai K, Sakai Y, Sakai A, Nakamura M, Mizukoshi E, Kaneko S. Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013;13:191. [PMID: 23587162 DOI: 10.1186/1471-2407-13-191] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
312 Mizuguchi T, Nagayama M, Meguro M, Shibata T, Kaji S, Nobuoka T, Kimura Y, Furuhata T, Hirata K. Prognostic Impact of Surgical Complications and Preoperative Serum Hepatocyte Growth Factor in Hepatocellular Carcinoma Patients After Initial Hepatectomy. J Gastrointest Surg 2009;13:325-33. [DOI: 10.1007/s11605-008-0711-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
313 Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev 2012;:CD002799. [PMID: 22972059 DOI: 10.1002/14651858.CD002799.pub2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
314 Poch FGM, Neizert CA, Geyer B, Gemeinhardt O, Bruder L, Niehues SM, Vahldiek JL, Bressem KK, Kreis ME, Lehmann KS. Influence of interapplicator distance on multibipolar radiofrequency ablation during physiological and interrupted liver perfusion in an in vivo porcine model. Sci Rep 2020;10:16210. [PMID: 33004845 DOI: 10.1038/s41598-020-71512-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
315 Ma KW, Chok KSH, Fung JYY, Lo CM. Liver Transplantation for Hepatitis B Virus-related Hepatocellular Carcinoma in Hong Kong. J Clin Transl Hepatol 2018;6:283-8. [PMID: 30271740 DOI: 10.14218/JCTH.2017.00058] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
316 Yeh CC, Lin JT, Jeng LB, Charalampos I, Chen TT, Lee TY, Wu MS, Kuo KN, Liu YY, Wu CY. Hepatic resection for hepatocellular carcinoma patients on hemodialysis for uremia: a nationwide cohort study. World J Surg. 2013;37:2402-2409. [PMID: 23811792 DOI: 10.1007/s00268-013-2137-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
317 Wei S, Hao X, Zhan D, Xiong M, Li K, Chen X, Huang Z. Are surgical indications of Barcelona Clinic Liver Cancer staging classification justified? J Huazhong Univ Sci Technolog Med Sci. 2011;31:637-641. [PMID: 22038353 DOI: 10.1007/s11596-011-0574-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
318 Gabrielson A, Tesfaye AA, Marshall JL, Pishvaian MJ, Smaglo B, Jha R, Dorsch-Vogel K, Wang H, He AR. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2015;76:1073-9. [PMID: 26449224 DOI: 10.1007/s00280-015-2852-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
319 Chen YX, Zeng ZC, Sun J, Zeng HY, Huang Y, Zhang ZY. Mesenchymal stem cell-conditioned medium prevents radiation-induced liver injury by inhibiting inflammation and protecting sinusoidal endothelial cells. J Radiat Res 2015;56:700-8. [PMID: 26070321 DOI: 10.1093/jrr/rrv026] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
320 Lin YT, Jeng LB, Chan WL, Su IJ, Teng CF. Hepatitis B Virus Pre-S Gene Deletions and Pre-S Deleted Proteins: Clinical and Molecular Implications in Hepatocellular Carcinoma. Viruses 2021;13:862. [PMID: 34066744 DOI: 10.3390/v13050862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
321 Choi D, Lim HK, Rhim H, Kim YS, Lee WJ, Paik SW, Koh KC, Lee JH, Choi MS, Yoo BC. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol. 2007;17:684-692. [PMID: 17093964 DOI: 10.1007/s00330-006-0461-5] [Cited by in Crossref: 229] [Cited by in F6Publishing: 218] [Article Influence: 14.3] [Reference Citation Analysis]
322 Ling TC, Kang JI, Bush DA, Slater JD, Yang GY. Proton therapy for hepatocellular carcinoma. Chin J Cancer Res 2012;24:361-7. [PMID: 23359779 DOI: 10.3978/j.issn.1000-9604.2012.10.09] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
323 Zeng Z, Ren J, O’Neil M, Zhao J, Bridges B, Cox J, Abdulkarim B, Schmitt TM, Kumer SC, Weinman SA. Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation. BMC Cancer. 2012;12:584. [PMID: 23216644 DOI: 10.1186/1471-2407-12-584] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
324 Di Maso V, Avellini C, Crocè LS, Rosso N, Quadrifoglio F, Cesaratto L, Codarin E, Bedogni G, Beltrami CA, Tell G, Tiribelli C. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med 2007;13:89-96. [PMID: 17515960 DOI: 10.2119/2006-00084.dimaso] [Cited by in Crossref: 66] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
325 Dai QS, Gu HL, Ye S, Zhang YJ, Lin XJ, Lau WY, Peng ZW, Chen MS. Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study. Mol Clin Oncol. 2014;2:1047-1054. [PMID: 25279196 DOI: 10.3892/mco.2014.391] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
326 Zhang Z, Zhou X, Shen H, Wang D, Wang Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med. 2009;7:41. [PMID: 19698189 DOI: 10.1186/1741-7015-7-41] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 6.9] [Reference Citation Analysis]
327 Zhao H, Guo Y, Li S, Han R, Ying J, Zhu H, Wang Y, Yin L, Han Y, Sun L, Wang Z, Lin Q, Bi X, Jiao Y, Jia H, Zhao J, Huang Z, Li Z, Zhou J, Song W, Meng K, Cai J. A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway. Oncotarget 2015;6:31927-43. [PMID: 26376676 DOI: 10.18632/oncotarget.5578] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 9.8] [Reference Citation Analysis]
328 Zhao H, Zhai X, Chen Z, Wan X, Chen L, Shen F, Ling C. Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma. Oncotarget 2017;8:45234-41. [PMID: 28423370 DOI: 10.18632/oncotarget.16804] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
329 Horváth Z, Kovalszky I, Fullár A, Kiss K, Schaff Z, Iozzo RV, Baghy K. Decorin deficiency promotes hepatic carcinogenesis. Matrix Biol 2014;35:194-205. [PMID: 24361483 DOI: 10.1016/j.matbio.2013.11.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 5.6] [Reference Citation Analysis]
330 Panebianco M, Ragazzi M, Asensio NM, Pagano M, Gnoni R, Boni C. A case of necrotizing vasculitis with panniculitis, during sorafenib treatment for hepatocellular carcinoma, appeared in disease progression. J Gastrointest Oncol 2014;5:E121-4. [PMID: 25436135 DOI: 10.3978/j.issn.2078-6891.2014.079] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
331 Jung HI, Ahn T, Bae SH, Chung JC, Kim H, Chin S, Jeong D, Cho HD, Lee MS, Kim HC, Kim CH, Baek MJ. Astrocyte elevated gene-1 overexpression in hepatocellular carcinoma: an independent prognostic factor. Ann Surg Treat Res 2015;88:77-85. [PMID: 25692118 DOI: 10.4174/astr.2015.88.2.77] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
332 Zugazagoitia J, Manzano A, Sastre J, Ladero JM, Puente J, Díaz-Rubio E. Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function. Clin Transl Oncol. 2013;15:146-153. [PMID: 22875650 DOI: 10.1007/s12094-012-0902-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
333 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 310] [Article Influence: 28.2] [Reference Citation Analysis]
334 Uemura T, Kirichenko A, Bunker M, Vincent M, Machado L, Thai N. Stereotactic Body Radiation Therapy: A New Strategy for Loco-Regional Treatment for Hepatocellular Carcinoma While Awaiting Liver Transplantation. World J Surg 2019;43:886-93. [PMID: 30361748 DOI: 10.1007/s00268-018-4829-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
335 Jin YJ, Cho SG, Lee KY, Kim JM, Lee JW. Association between relative liver enhancement on gadoxetic acid enhanced magnetic resonance images and histologic grade of hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e7580. [PMID: 28746206 DOI: 10.1097/MD.0000000000007580] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
336 Sonohara F, Nomoto S, Inokawa Y, Kanda M, Yamada S, Fujii T, Sugimoto H, Kodera Y. Serosal invasion strongly associated with recurrence after curative hepatic resection of hepatocellular carcinoma: a retrospective study of 214 consecutive cases. Medicine (Baltimore) 2015;94:e602. [PMID: 25738484 DOI: 10.1097/MD.0000000000000602] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
337 Chadha AS, Gunther JR, Hsieh CE, Aliru M, Mahadevan LS, Venkatesulu BP, Crane CH, Das P, Herman JM, Koay EJ, Taniguchi C, Holliday EB, Minsky BD, Suh Y, Park P, Sawakuchi G, Beddar S, Odisio BC, Gupta S, Loyer E, Kaur H, Raghav K, Javle MM, Kaseb AO, Krishnan S. Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiother Oncol 2019;133:54-61. [PMID: 30935582 DOI: 10.1016/j.radonc.2018.10.041] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
338 Wu FX, Chen J, Bai T, Zhu SL, Yang TB, Qi LN, Zou L, Li ZH, Ye JZ, Li LQ. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. BMC Cancer 2017;17:645. [PMID: 28899349 DOI: 10.1186/s12885-017-3545-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
339 Ke M, Xu T, Li N, Ren Y, Shi A, Lv Y, He H. Prognostic nutritional index predicts short-term outcomes after liver resection for hepatocellular carcinoma within the Milan criteria. Oncotarget 2016;7:81611-20. [PMID: 27835570 DOI: 10.18632/oncotarget.13151] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
340 Chen XP, Long X, Jia WL, Wu HJ, Zhao J, Liang HF, Laurence A, Zhu J, Dong D, Chen Y, Lin L, Xia YD, Li WY, Li GB, Zhao ZK, Wu K, Hou Y, Yu JJ, Xiao W, Wang GP, Zhu PC, Chen W, Bai MZ, Jian YX, Kristiansen K, Chen Q. Viral integration drives multifocal HCC during the occult HBV infection. J Exp Clin Cancer Res 2019;38:261. [PMID: 31200735 DOI: 10.1186/s13046-019-1273-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
341 Hu S, Liu J, Feng S, Wang Y, Liu H. LncRNA SUMO1P3 acts as a prognostic biomarker and promotes hepatocellular carcinoma growth and metastasis. Aging (Albany NY) 2021;13:12479-92. [PMID: 33902004 DOI: 10.18632/aging.202921] [Reference Citation Analysis]
342 Yin YH, Li YY, Qiao H, Wang HC, Yang XA, Zhang HG, Pang XW, Zhang Y, Chen WF. TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma. Br J Cancer. 2005;93:458-463. [PMID: 16106251 DOI: 10.1038/sj.bjc.6602716] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 2.6] [Reference Citation Analysis]
343 Cao MT, Liu HF, Liu ZG, Xiao P, Chen JJ, Tan Y, Jiang XX, Jiang ZC, Qiu Y, Huang HJ, Zhang QG, Jiang GM. Curcumin downregulates the expression of Snail via suppressing Smad2 pathway to inhibit TGF-β1-induced epithelial-mesenchymal transitions in hepatoma cells. Oncotarget 2017;8:108498-508. [PMID: 29312546 DOI: 10.18632/oncotarget.22590] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
344 Demir M, Grünewald F, Lang S, Schramm C, Bowe A, Mück V, Kütting F, Goeser T, Steffen HM. Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients. Medicine (Baltimore) 2016;95:e4602. [PMID: 27661015 DOI: 10.1097/MD.0000000000004602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
345 Choi HJ, Cho BC, Sohn JH, Shin SJ, Kim SH, Kim JH, Yoo NC. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol. 2009;91:307-313. [PMID: 18949445 DOI: 10.1007/s11060-008-9713-3] [Cited by in Crossref: 81] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
346 Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, Maeda H, Matsuo K, Nishida N, Aramaki T, Anai H, Koura S, Oikawa S, Watanabe K, Yasumoto T, Furuichi K, Yamaguchi M. Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization. Jpn J Radiol 2014;32:260-5. [PMID: 24615165 DOI: 10.1007/s11604-014-0298-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
347 Quint K, Agaimy A, Di Fazio P, Montalbano R, Steindorf C, Jung R, Hellerbrand C, Hartmann A, Sitter H, Neureiter D, Ocker M. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch 2011;459:129-39. [PMID: 21713366 DOI: 10.1007/s00428-011-1103-0] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 7.2] [Reference Citation Analysis]
348 Bartlett ASJR, McCall JL, Koea JB, Holden A, Yeong ML, Gurusinghe N, Gane E. Liver resection for hepatocellular carcinoma in a hepatitis B endemic area. World J Surg 2007;31:1775-81. [PMID: 17610112 DOI: 10.1007/s00268-007-9069-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
349 Fu YP, Yi Y, Cai XY, Sun J, Ni XC, He HW, Wang JX, Lu ZF, Huang JL, Cao Y, Zhou J, Fan J, Qiu SJ. Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Br J Cancer. 2016;114:767-776. [PMID: 27002937 DOI: 10.1038/bjc.2016.47] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 6.8] [Reference Citation Analysis]
350 Rajasekaran D, Srivastava J, Ebeid K, Gredler R, Akiel M, Jariwala N, Robertson CL, Shen XN, Siddiq A, Fisher PB, Salem AK, Sarkar D. Combination of Nanoparticle-Delivered siRNA for Astrocyte Elevated Gene-1 (AEG-1) and All-trans Retinoic Acid (ATRA): An Effective Therapeutic Strategy for Hepatocellular Carcinoma (HCC). Bioconjug Chem 2015;26:1651-61. [PMID: 26079152 DOI: 10.1021/acs.bioconjchem.5b00254] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
351 Gentschev I, Müller M, Adelfinger M, Weibel S, Grummt F, Zimmermann M, Bitzer M, Heisig M, Zhang Q, Yu YA, Chen NG, Stritzker J, Lauer UM, Szalay AA. Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68. PLoS One 2011;6:e22069. [PMID: 21779374 DOI: 10.1371/journal.pone.0022069] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
352 Liu M, Zhang L, Li H, Hinoue T, Zhou W, Ohtani H, El-Khoueiry A, Daniels J, O'Connell C, Dorff TB, Lu Q, Weisenberger DJ, Liang G. Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 2018;68:1412-28. [PMID: 29774579 DOI: 10.1002/hep.30091] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
353 Ogasawara S, Kanai F, Obi S, Sato S, Yamaguchi T, Azemoto R, Mizumoto H, Koushima Y, Morimoto N, Hirata N. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int. 2011;5:850-856. [PMID: 21484134 DOI: 10.1007/s12072-010-9249-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
354 Liu M, Zheng SJ, Chen Y, Li N, Ren PF, Dai LP, Duan ZP, Zhang JY. Autoantibody response to murine double minute 2 protein in immunodiagnosis of hepatocellular carcinoma. J Immunol Res. 2014;2014:906532. [PMID: 24955377 DOI: 10.1155/2014/906532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
355 Liu PH, Su CW, Hsu CY, Hsia CY, Lee YH, Huang YH, Lee RC, Lin HC, Huo TI. Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy. PLoS One. 2016;11:e0155588. [PMID: 27176037 DOI: 10.1371/journal.pone.0155588] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
356 Liu W, Wang N, Lu M, Du XJ, Xing BC. MBD2 as a novel marker associated with poor survival of patients with hepatocellular carcinoma after hepatic resection. Mol Med Rep 2016;14:1617-23. [PMID: 27315121 DOI: 10.3892/mmr.2016.5404] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
357 Wu YH, Ai X, Liu FY, Liang HF, Zhang BX, Chen XP. c-Jun N-terminal kinase inhibitor favors transforming growth factor-β to antagonize hepatitis B virus X protein-induced cell growth promotion in hepatocellular carcinoma. Mol Med Rep 2016;13:1345-52. [PMID: 26648552 DOI: 10.3892/mmr.2015.4644] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
358 Li H, Miao Q, Xu CW, Huang JH, Zhou YF, Wu MJ. OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway. J Korean Med Sci 2016;31:1215-23. [PMID: 27478331 DOI: 10.3346/jkms.2016.31.8.1215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
359 Wang ZS, Wu LQ, Yi X, Geng C, Li YJ, Yao RY. Connexin-43 can delay early recurrence and metastasis in patients with hepatitis B-related hepatocellular carcinoma and low serum alpha-fetoprotein after radical hepatectomy. BMC Cancer 2013;13:306. [PMID: 23800357 DOI: 10.1186/1471-2407-13-306] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
360 Kudo M, Tateishi R, Yamashita T, Ikeda M, Furuse J, Ikeda K, Kokudo N, Izumi N, Matsui O. Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system. Clin Drug Investig 2012;32 Suppl 2:37-51. [PMID: 22873626 DOI: 10.1007/BF03265495] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
361 Waly Raphael S, Yangde Z, Yuxiang C. Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol 2012;2012:421673. [PMID: 22655206 DOI: 10.5402/2012/421673] [Cited by in Crossref: 25] [Cited by in F6Publishing: 45] [Article Influence: 2.5] [Reference Citation Analysis]
362 Bartosiewicz AJ, Mikuła T. Hepatocellular carcinoma after direct-acting antivirals: an unresolved problem. Review of five cases. Clin Exp Hepatol 2019;5:88-92. [PMID: 30915412 DOI: 10.5114/ceh.2019.83162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
363 Wang H, Pan K, Zhang HK, Weng DS, Zhou J, Li JJ, Huang W, Song HF, Chen MS, Xia JC. Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134:535-541. [PMID: 17917742 DOI: 10.1007/s00432-007-0316-8] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 4.9] [Reference Citation Analysis]
364 Tang CW, Zhu M, Feng WM, Bao Y, Zheng YY. Chinese herbal medicine, Jianpi Ligan decoction, improves prognosis of unresectable hepatocellular carcinoma after transarterial chemoembolization: a retrospective study. Drug Des Devel Ther 2016;10:2461-6. [PMID: 27536066 DOI: 10.2147/DDDT.S113295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
365 Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107:569-77; quiz 578. [PMID: 22158026 DOI: 10.1038/ajg.2011.425] [Cited by in Crossref: 406] [Cited by in F6Publishing: 385] [Article Influence: 36.9] [Reference Citation Analysis]
366 Orloff MJ, Isenberg JI, Wheeler HO, Haynes KS, Jinich-Brook H, Rapier R, Vaida F, Hye RJ, Orloff SL. A randomized controlled trial of emergency treatment of bleeding esophageal varices in cirrhosis for hepatocellular carcinoma. Am J Surg 2012;203:182-90. [PMID: 21679921 DOI: 10.1016/j.amjsurg.2011.02.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
367 Harvin JA, Van Buren G, Tsao K, Cen P, Ko TC, Wray CJ. Hepatocellular carcinoma survival in uninsured and underinsured patients. J Surg Res 2011;166:189-93. [PMID: 20638680 DOI: 10.1016/j.jss.2010.04.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
368 Chen XL, Xu YY, Chen L, Wang GL, Shen Y. TLR3 Plays Significant Roles against HBV-Associated HCC. Gastroenterol Res Pract 2015;2015:572171. [PMID: 25983748 DOI: 10.1155/2015/572171] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
369 Gong K, Chen C, Zhan Y, Chen Y, Huang Z, Li W. Autophagy-related gene 7 (ATG7) and reactive oxygen species/extracellular signal-regulated kinase regulate tetrandrine-induced autophagy in human hepatocellular carcinoma. J Biol Chem 2012;287:35576-88. [PMID: 22927446 DOI: 10.1074/jbc.M112.370585] [Cited by in Crossref: 89] [Cited by in F6Publishing: 43] [Article Influence: 8.9] [Reference Citation Analysis]
370 Umeda Y, Matsuda H, Sadamori H, Matsukawa H, Yagi T, Fujiwara T. A prognostic model and treatment strategy for intrahepatic recurrence of hepatocellular carcinoma after curative resection. World J Surg. 2011;35:170-177. [PMID: 20922387 DOI: 10.1007/s00268-010-0794-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
371 Vongchan P, Wutti-In Y, Sajomsang W, Gonil P, Kothan S, Linhardt RJ. N,N,N-Trimethyl chitosan nanoparticles for the delivery of monoclonal antibodies against hepatocellular carcinoma cells. Carbohydr Polym 2011;85:215-20. [PMID: 21552341 DOI: 10.1016/j.carbpol.2011.02.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
372 Kim SE, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center. Korean J Hepatol. 2011;17:113-119. [PMID: 21757982 DOI: 10.3350/kjhep.2011.17.2.113] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
373 Zhang J, Yang JM, Wang HJ, Ru GQ, Fan DM. Synthesized multiple antigenic polypeptide vaccine based on B-cell epitopes of human heparanase could elicit a potent antimetastatic effect on human hepatocellular carcinoma in vivo. PLoS One 2013;8:e52940. [PMID: 23308126 DOI: 10.1371/journal.pone.0052940] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
374 Kamimura K, Suda T, Tamura Y, Takamura M, Yokoo T, Igarashi M, Kawai H, Yamagiwa S, Nomoto M, Aoyagi Y. Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma. BMC Gastroenterol 2012;12:127. [PMID: 22994941 DOI: 10.1186/1471-230X-12-127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
375 Fu X, Wan S, Hann HW, Myers RE, Hann RS, Au J, Chen B, Xing J, Yang H. Relative telomere length: a novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection. Eur J Cancer 2012;48:1014-22. [PMID: 22444598 DOI: 10.1016/j.ejca.2012.02.066] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
376 Tu JF, Ding YH, Chen L, Ying XH, Zhang DK, Wu FZ, Zhao ZW, Ji JS, Zhang WG, Zou H. Iodine-125 Brachytherapy Prophylaxis after Radiofrequency Ablation Cannot Benefit Patients in High Risk of Locoregional Hepatocellular Carcinoma Recurrence. Sci Rep 2017;7:3689. [PMID: 28623296 DOI: 10.1038/s41598-017-03831-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
377 Kang JY, Choi MS, Kim SJ, Kil JS, Lee JH, Koh KC, Paik SW, Yoo BC. Long-term outcome of preoperative transarterial chemoembolization and hepatic resection in patients with hepatocellular carcinoma. Korean J Hepatol. 2010;16:383-388. [PMID: 21415582 DOI: 10.3350/kjhep.2010.16.4.383] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
378 Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM. Cancer gene discovery in hepatocellular carcinoma. J Hepatol. 2010;52:921-929. [PMID: 20385424 DOI: 10.1016/j.jhep.2009.12.034] [Cited by in Crossref: 120] [Cited by in F6Publishing: 113] [Article Influence: 10.0] [Reference Citation Analysis]
379 Cong WM, Wu MC. Small hepatocellular carcinoma: current and future approaches. Hepatol Int. 2013;7:805-812. [PMID: 26201917 DOI: 10.1007/s12072-013-9454-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
380 Li JJ, Pan K, Gu MF, Chen MS, Zhao JJ, Wang H, Liang XT, Sun JC, Xia JC. Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma. Chin J Cancer. 2013;32:141-148. [PMID: 22704489 DOI: 10.5732/cjc.012.10025] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
381 Shi L, Zhang W, Zou F, Mei L, Wu G, Teng Y. KLHL21, a novel gene that contributes to the progression of hepatocellular carcinoma. BMC Cancer 2016;16:815. [PMID: 27769251 DOI: 10.1186/s12885-016-2851-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
382 Ye SL, Chen X, Yang J, Bie P, Zhang S, Liu F, Liu L, Zhou J, Dou K, Hao C, Shao G, Xia Q, Chen Y, Yang J, Deng X, Liu Y, Yuan Y, Fu Z, Nakajima K, Yip CS, Lu Z. Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. Oncotarget 2016;7:6639-48. [PMID: 26735891 DOI: 10.18632/oncotarget.6781] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
383 Matsuura Y, Wada H, Eguchi H, Gotoh K, Kobayashi S, Kinoshita M, Kubo M, Hayashi K, Iwagami Y, Yamada D, Asaoka T, Noda T, Kawamoto K, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. Exosomal miR-155 Derived from Hepatocellular Carcinoma Cells Under Hypoxia Promotes Angiogenesis in Endothelial Cells. Dig Dis Sci 2019;64:792-802. [PMID: 30465177 DOI: 10.1007/s10620-018-5380-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 7.5] [Reference Citation Analysis]
384 Jin YJ, Aycheh HM, Han S, Chamberlin J, Shin J, Byun S, Lee Y. Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein. BMC Med Genomics 2020;13:194. [PMID: 33371894 DOI: 10.1186/s12920-020-00836-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
385 Lin Y, Jeng L, Su I, Teng C. Approaches for Detection of Hepatitis B Virus Pre-S Gene Deletions and Pre-S Deleted Proteins and Their Application in Prediction of Higher Risk of Hepatocellular Carcinoma Development and Recurrence. Viruses 2022;14:428. [DOI: 10.3390/v14020428] [Reference Citation Analysis]
386 Yang JD. Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clin Mol Hepatol 2019;25:335-43. [PMID: 30924328 DOI: 10.3350/cmh.2019.0010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
387 Miraglia R, Pietrosi G, Maruzzelli L, Petridis I, Caruso S, Marrone G, Mamone G, Vizzini G, Luca A, Gridelli B. Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. World J Gastroenterol 2007;13:6022-6. [PMID: 18023093 DOI: 10.3748/wjg.v13.45.6022] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
388 Chang AY, Wang M. Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells. BMC Cancer 2013;13:267. [PMID: 23721490 DOI: 10.1186/1471-2407-13-267] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
389 Kuramitsu K, Sverdlov DY, Liu SB, Csizmadia E, Burkly L, Schuppan D, Hanto DW, Otterbein LE, Popov Y. Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation. Am J Pathol. 2013;183:182-194. [PMID: 23680654 DOI: 10.1016/j.ajpath.2013.03.018] [Cited by in Crossref: 66] [Cited by in F6Publishing: 76] [Article Influence: 7.3] [Reference Citation Analysis]
390 Brace CL, Laeseke PF, van der Weide DW, Lee FT. Microwave Ablation With a Triaxial Antenna: Results in ex vivo Bovine Liver. IEEE Trans Microw Theory Tech. 2005;53:215-220. [PMID: 18079981 DOI: 10.1109/tmtt.2004.839308] [Cited by in Crossref: 80] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
391 Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis. 2012;12 Suppl 2:S2. [PMID: 23173556 DOI: 10.1186/1471-2334-12-s2-s2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
392 Mikami D, Kobayashi M, Uwada J, Yazawa T, Kamiyama K, Nishimori K, Nishikawa Y, Nishikawa S, Yokoi S, Taniguchi T, Iwano M. AR420626, a selective agonist of GPR41/FFA3, suppresses growth of hepatocellular carcinoma cells by inducing apoptosis via HDAC inhibition. Ther Adv Med Oncol 2020;12:1758835920913432. [PMID: 33014144 DOI: 10.1177/1758835920913432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
393 Xu H, Mao Y. A brief comment on liver resection for hepatocellular carcinoma. Gastroenterol Rep (Oxf) 2013;1:184-5. [PMID: 24759963 DOI: 10.1093/gastro/got019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
394 Yin JM, Sun LB, Zheng JS, Wang XX, Chen DX, Li N. Copper chelation by trientine dihydrochloride inhibits liver RFA-induced inflammatory responses in vivo. Inflamm Res 2016;65:1009-20. [PMID: 27613237 DOI: 10.1007/s00011-016-0986-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
395 Greten TF, Manns MP, Reinisch I, Kaatsch P. Hepatocellular carcinoma occurring after successful treatment of childhood cancer with high dose chemotherapy and radiation. Gut. 2005;54:732. [PMID: 15831932 DOI: 10.1136/gut.2004.059352] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
396 Guo JH, Zhu X, Li XT, Yang RJ. Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Chin J Cancer Res 2012;24:36-43. [PMID: 23359473 DOI: 10.1007/s11670-012-0036-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
397 Huang ZJ, Zhu JJ, Yang XY, Biskup E. NEDD4 promotes cell growth and migration via PTEN/PI3K/AKT signaling in hepatocellular carcinoma. Oncol Lett 2017;14:2649-56. [PMID: 28928809 DOI: 10.3892/ol.2017.6532] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
398 Abbas EAER, Barakat AB, Hassany M, Youssef SS. The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients. J Genet Eng Biotechnol 2022;20:4. [PMID: 34978646 DOI: 10.1186/s43141-021-00282-4] [Reference Citation Analysis]
399 Yuan X, Chen H, Li X, Dai M, Zeng H, Shan L, Sun Q, Zhang W. Inhibition of protein kinase C by isojacareubin suppresses hepatocellular carcinoma metastasis and induces apoptosis in vitro and in vivo. Sci Rep 2015;5:12889. [PMID: 26245668 DOI: 10.1038/srep12889] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
400 Hsu KY, Chau GY, Lui WY, Tsay SH, King KL, Wu CW. Predicting morbidity and mortality after hepatic resection in patients with hepatocellular carcinoma: the role of Model for End-Stage Liver Disease score. World J Surg. 2009;33:2412-2419. [PMID: 19756859 DOI: 10.1007/s00268-009-0202-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
401 Guzman G, Chennuri R, Chan A, Rea B, Quintana A, Patel R, Xu PZ, Xie H, Hay N. Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma. Dig Dis Sci 2015;60:420-6. [PMID: 25381201 DOI: 10.1007/s10620-014-3364-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
402 Sagmeister S, Eisenbauer M, Pirker C, Mohr T, Holzmann K, Zwickl H, Bichler C, Kandioler D, Wrba F, Mikulits W, Gerner C, Shehata M, Majdic O, Streubel B, Berger W, Micksche M, Zatloukal K, Schulte-Hermann R, Grasl-Kraupp B. New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis. Br J Cancer 2008;99:151-9. [PMID: 18594539 DOI: 10.1038/sj.bjc.6604440] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
403 Mir O, Coriat R, Boudou-Rouquette P, Ropert S, Durand JP, Cessot A, Mallet V, Sogni P, Chaussade S, Pol S. Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. Med Oncol. 2012;29:2793-2799. [PMID: 22427209 DOI: 10.1007/s12032-012-0208-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
404 Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One 2014;9:e90929. [PMID: 24603710 DOI: 10.1371/journal.pone.0090929] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
405 Ju MJ, Qiu SJ, Fan J, Zhou J, Gao Q, Cai MY, Li YW, Tang ZY. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol. 2009;44:635-642. [PMID: 19387533 DOI: 10.1007/s00535-009-0050-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
406 Lee C, Yun J, Yim Y. The Effect of Gamisoyo-san Intravenous Pharmacopuncture on Restoration of Liver Function after Partial Hepatectomy in SD Rat. J Korean Med 2015;36:22-32. [DOI: 10.13048/jkm.15003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
407 Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer. 2005;92:607-612. [PMID: 15685242 DOI: 10.1038/sj.bjc.6602333] [Cited by in Crossref: 118] [Cited by in F6Publishing: 123] [Article Influence: 6.9] [Reference Citation Analysis]
408 Gabrielson A, Miller A, Banovac F, Kim A, He AR, Unger K. Outcomes and Predictors of Toxicity after Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres for Unresectable Hepatocellular Carcinoma. Front Oncol 2015;5:292. [PMID: 26779437 DOI: 10.3389/fonc.2015.00292] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
409 Duan JL, Nie RC, Xiang ZC, Chen JW, Deng MH, Liang H, Wang FW, Luo RZ, Xie D, Cai MY. Prognostic Model for the Risk Stratification of Early and Late Recurrence in Hepatitis B Virus-Related Small Hepatocellular Carcinoma Patients with Global Histone Modifications. J Hepatocell Carcinoma 2021;8:493-505. [PMID: 34095004 DOI: 10.2147/JHC.S309451] [Reference Citation Analysis]
410 Vashist YK, Tiffon C, Stoupis C, Redaelli CA. Inhibition of hepatic tumor cell proliferation in vitro and tumor growth in vivo by taltobulin, a synthetic analogue of the tripeptide hemiasterlin. World J Gastroenterol 2006; 12(42): 6771-6778 [PMID: 17106924 DOI: 10.3748/wjg.v12.i42.6771] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
411 Kim DH, Choy T, Huang S, Green RM, Omary RA, Larson AC. Microfluidic fabrication of 6-methoxyethylamino numonafide-eluting magnetic microspheres. Acta Biomater 2014;10:742-50. [PMID: 24161384 DOI: 10.1016/j.actbio.2013.10.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
412 Yang S, Lin Q, Lin W, Hu W, Wang G. Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: a systematic review. World J Surg Oncol 2016;14:159. [PMID: 27282382 DOI: 10.1186/s12957-016-0912-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
413 Zhao K, Xu L, Li F, Ao J, Jiang G, Shi R, Chen F, Luo Q. Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature. Biosci Rep 2020;40:BSR20200894. [PMID: 32789471 DOI: 10.1042/BSR20200894] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
414 Krishna Prasad BP, Ray B. Agitated saline sonography: a simple technique for intraprocedural feeder identification during transcatheter arterial chemoembolization of hepatocellular carcinoma. Diagn Interv Radiol 2016;22:269-72. [PMID: 27015444 DOI: 10.5152/dir.2015.15356] [Reference Citation Analysis]
415 Zhuang PY, Shen J, Zhu XD, Lu L, Wang L, Tang ZY, Sun HC. Prognostic roles of cross-talk between peritumoral hepatocytes and stromal cells in hepatocellular carcinoma involving peritumoral VEGF-C, VEGFR-1 and VEGFR-3. PLoS One. 2013;8:e64598. [PMID: 23737988 DOI: 10.1371/journal.pone.0064598] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
416 Lin J, Wu L, Bai X, Xie Y, Wang A, Zhang H, Yang X, Wan X, Lu X, Sang X, Zhao H. Combination treatment including targeted therapy for advanced hepatocellular carcinoma. Oncotarget 2016;7:71036-51. [PMID: 27626176 DOI: 10.18632/oncotarget.11954] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
417 Shindoh J, Hasegawa K, Inoue Y, Ishizawa T, Nagata R, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M, Kokudo N. Risk factors of post-operative recurrence and adequate surgical approach to improve long-term outcomes of hepatocellular carcinoma. HPB (Oxford). 2013;15:31-39. [PMID: 23216777 DOI: 10.1111/j.1477-2574.2012.00552.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 6.3] [Reference Citation Analysis]
418 Ko HK, Ko GY, Yoon HK, Sung KB. Tumor response to transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation. Korean J Radiol. 2007;8:320-327. [PMID: 17673843 DOI: 10.3348/kjr.2007.8.4.320] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
419 Vainshtein JM, Kabarriti R, Mehta KJ, Roy-Chowdhury J, Guha C. Bone marrow-derived stromal cell therapy in cirrhosis: clinical evidence, cellular mechanisms, and implications for the treatment of hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2014;89:786-803. [PMID: 24969793 DOI: 10.1016/j.ijrobp.2014.02.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
420 Hoffmann K, Ganten T, Gotthardtp D, Radeleff B, Settmacher U, Kollmar O, Nadalin S, Karapanagiotou-Schenkel I, von Kalle C, Jäger D, Büchler MW, Schemmer P. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial. BMC Cancer 2015;15:392. [PMID: 25957784 DOI: 10.1186/s12885-015-1373-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
421 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
422 Bruera G, Cannita K, Giordano AV, Manetta R, Vicentini R, Carducci S, Saltarelli P, Iapadre N, Coletti G, Ficorella C. Multidisciplinary management of hepatocellular carcinoma in clinical practice. Biomed Res Int. 2014;2014:806391. [PMID: 24900987 DOI: 10.1155/2014/806391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
423 Guo Y, Zhao J, Bi J, Wu Q, Wang X, Lai Q. Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis. J Hematol Oncol 2012;5:37. [PMID: 22760167 DOI: 10.1186/1756-8722-5-37] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
424 Ryu JW, Kim SK, Son MY, Jeon SJ, Oh JH, Lim JH, Cho S, Jung CR, Hamamoto R, Kim DS, Cho HS. Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC. Oncotarget 2017;8:115444-55. [PMID: 29383172 DOI: 10.18632/oncotarget.23296] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
425 Lee IJ, Seong J. The optimal selection of radiotherapy treatment for hepatocellular carcinoma. Gut Liver 2012;6:139-48. [PMID: 22570744 DOI: 10.5009/gnl.2012.6.2.139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
426 Bertino G, Demma S, Ardiri A, Proiti M, Mangia A, Gruttadauria S, Toro A, Di Carlo I, Malaguarnera G, Bertino N. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed Res Int. 2015;2015:731469. [PMID: 25893197 DOI: 10.1155/2015/731469] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
427 Geissler EK, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, Duvoux C, Burra P, Jauch KW, Rentsch M, Ganten TM, Schmidt J, Settmacher U, Heise M, Rossi G, Cillo U, Kneteman N, Adam R, van Hoek B, Bachellier P, Wolf P, Rostaing L, Bechstein WO, Rizell M, Powell J, Hidalgo E, Gugenheim J, Wolters H, Brockmann J, Roy A, Mutzbauer I, Schlitt A, Beckebaum S, Graeb C, Nadalin S, Valente U, Turrión VS, Jamieson N, Scholz T, Colledan M, Fändrich F, Becker T, Söderdahl G, Chazouillères O, Mäkisalo H, Pageaux GP, Steininger R, Soliman T, de Jong KP, Pirenne J, Margreiter R, Pratschke J, Pinna AD, Hauss J, Schreiber S, Strasser S, Klempnauer J, Troisi RI, Bhoori S, Lerut J, Bilbao I, Klein CG, Königsrainer A, Mirza DF, Otto G, Mazzaferro V, Neuhaus P, Schlitt HJ. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation 2016;100:116-25. [PMID: 26555945 DOI: 10.1097/TP.0000000000000965] [Cited by in Crossref: 189] [Cited by in F6Publishing: 83] [Article Influence: 31.5] [Reference Citation Analysis]
428 Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, El-Serag HB, Hawk E, Morris J, Singh Raghav KP, Lee JS, Vauthey JN, Bortus G, Torres HA, Amos CI, Wolff RA, Li D. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology 2015;149:119-29. [PMID: 25836985 DOI: 10.1053/j.gastro.2015.03.044] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 9.3] [Reference Citation Analysis]
429 Goto E, Masuzaki R, Tateishi R, Kondo Y, Imamura J, Goto T, Ikeda H, Akahane M, Shiina S, Omata M, Yoshida H, Koike K. Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma. J Gastroenterol 2012;47:477-85. [PMID: 22200940 DOI: 10.1007/s00535-011-0512-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
430 Duan CL, Hou GH, Liu YP, Liang T, Song J, Han JK, Zhang C. Tumor vascular homing endgolin-targeted radioimmunotherapy in hepatocellular carcinoma. Tumour Biol 2014;35:12205-15. [PMID: 25164610 DOI: 10.1007/s13277-014-2529-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
431 Wang W, Feng X, Zhang T, Jin J, Wang S, Liu Y, Song Y, Liu X, Yu Z, Li Y. Prospective evaluation of microscopic extension using whole-mount preparation in patients with hepatocellular carcinoma: Definition of clinical target volume for radiotherapy. Radiat Oncol 2010;5:73. [PMID: 20731853 DOI: 10.1186/1748-717X-5-73] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
432 Bassi N, Caratozzolo E, Bonariol L, Ruffolo C, Bridda A, Padoan L, Antoniutti M, Massani M. Management of ruptured hepatocellular carcinoma: Implications for therapy. World J Gastroenterol 2010; 16(10): 1221-1225 [PMID: 20222165 DOI: 10.3748/wjg.v16.i10.1221] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
433 Patidar Y, Khisti R, Yadav A, Mukund A, Sarin SK. Outcome of conventional transarterial chemoembolization (cTACE) in the management of spontaneously ruptured hepatocellular carcinoma. Indian J Radiol Imaging 2019;29:177-81. [PMID: 31367089 DOI: 10.4103/ijri.IJRI_252_18] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
434 Bouhlal H, Ouled-Haddou H, Debuysscher V, Singh AR, Ossart C, Reignier A, Hocini H, Fouquet G, Al Baghami M, Eugenio MS, Nguyen-Khac E, Regimbeau JM, Marcq I. RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation. Oncotarget 2016;7:9832-43. [PMID: 26799423 DOI: 10.18632/oncotarget.6954] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
435 Khan OF, Zaia EW, Yin H, Bogorad RL, Pelet JM, Webber MJ, Zhuang I, Dahlman JE, Langer R, Anderson DG. Ionizable amphiphilic dendrimer-based nanomaterials with alkyl-chain-substituted amines for tunable siRNA delivery to the liver endothelium in vivo. Angew Chem Int Ed Engl 2014;53:14397-401. [PMID: 25354018 DOI: 10.1002/anie.201408221] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 5.8] [Reference Citation Analysis]
436 Han LY, Fan YC, Mu NN, Gao S, Li F, Ji XF, Dou CY, Wang K. Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B Virus associated hepatocellular carcinoma. Int J Med Sci 2014;11:164-71. [PMID: 24465162 DOI: 10.7150/ijms.6745] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
437 Li H, Shi S, Wu M, Shen W, Ren J, Mei Z, Ran H, Wang Z, Tian Y, Gao J, Zhao H. iRGD Peptide-Mediated Liposomal Nanoparticles with Photoacoustic/Ultrasound Dual-Modality Imaging for Precision Theranostics Against Hepatocellular Carcinoma. Int J Nanomedicine 2021;16:6455-75. [PMID: 34584411 DOI: 10.2147/IJN.S325891] [Reference Citation Analysis]
438 Yang Y, Lu Y, Wang C, Bai W, Qu J, Chen Y, Chang X, An L, Zhou L, Zeng Z, Lou M, Lv J. Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med. 2012;3:171-180. [PMID: 22969864 DOI: 10.3892/etm.2011.398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
439 Lin X, Wang Q, Cao Z, Geng M, Cao Y, Liu X. Differential Expression of Wnt Pathway Genes in Sporadic Hepatocellular Carcinomas Infected With Hepatitis B Virus Identified With OligoGE Arrays. Hepat Mon. 2013;13:e6192. [PMID: 23483081 DOI: 10.5812/hepatmon.6192] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
440 Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, Wang L, Wang J, Yuan Y. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 2011;9:166. [PMID: 21955323 DOI: 10.1186/1479-5876-9-166] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
441 Li Z, Lei Z, Xia Y, Li J, Wang K, Zhang H, Wan X, Yang T, Zhou W, Wu M, Pawlik TM, Lau WY, Shen F. Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma. JAMA Surg 2018;153:e182721. [PMID: 30073257 DOI: 10.1001/jamasurg.2018.2721] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
442 Liu Q, Yang Y, Tan X, Tao Z, Adah D, Yu S, Lu J, Zhao S, Qin L, Qin L, Chen X. Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector. Oncotarget 2017;8:24785-96. [PMID: 28445973 DOI: 10.18632/oncotarget.15806] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
443 Cecil A, Gentschev I, Adelfinger M, Dandekar T, Szalay AA. Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models. Bioengineered 2019;10:190-6. [PMID: 31142183 DOI: 10.1080/21655979.2019.1622220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
444 Zhou YM, Shao WY, Zhao YF, Xu DH, Li B. Meta-analysis of laparoscopic versus open resection for hepatocellular carcinoma. Dig Dis Sci. 2011;56:1937-1943. [PMID: 21259071 DOI: 10.1007/s10620-011-1572-7] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 6.7] [Reference Citation Analysis]
445 Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO. Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma 2016;3:1-7. [PMID: 27574586 DOI: 10.2147/JHC.S62261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
446 Saito Y, Matsuzaki Y, Honda A, Iwamoto J, Ikegami T, Chiba T, Sugahara S, Okumura T, Tsujii H, Doy M, Tokuuye K. Post-therapeutic needle biopsy in patients with hepatocellular carcinoma is a useful tool to evaluate response to proton irradiation. Hepatol Res 2014;44:403-9. [PMID: 23607877 DOI: 10.1111/hepr.12133] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
447 Nunes TF, Barbosa FC, Miiji LN, de Souza LG. Chemoembolisation combined with percutaneous radiofrequency ablation in the treatment of primary angiosarcoma of the liver.BMJ Case Rep. 2013;2013. [PMID: 23704445 DOI: 10.1136/bcr-2013-009511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
448 Granito A, Bolondi L. Medical treatment of hepatocellular carcinoma. Mediterr J Hematol Infect Dis 2009;1:e2009021. [PMID: 21415957 DOI: 10.4084/MJHID.2009.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
449 Tian X, Li J, Ma ZM, Zhao C, Wan DF, Wen YM. Role of hepatitis B surface antigen in the development of hepatocellular carcinoma: regulation of lymphoid enhancer-binding factor 1. J Exp Clin Cancer Res. 2009;28:58. [PMID: 19402906 DOI: 10.1186/1756-9966-28-58] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
450 Qu XD, Chen CS, Wang JH, Yan ZP, Chen JM, Gong GQ, Liu QX, Luo JJ, Liu LX, Liu R, Qian S. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC Cancer. 2012;12:263. [PMID: 22721173 DOI: 10.1186/1471-2407-12-263] [Cited by in Crossref: 52] [Cited by in F6Publishing: 64] [Article Influence: 5.2] [Reference Citation Analysis]
451 Unek T, Karademir S, Arslan NC, Egeli T, Atasoy G, Sagol O, Obuz F, Akarsu M, Astarcioglu I. Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma. World J Gastroenterol 2011; 17(37): 4206-4212 [PMID: 22072852 DOI: 10.3748/wjg.v17.i37.4206] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
452 Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, Yersiz H, Lu DS, Lassman C, Tong MJ, Hiatt JR, Busuttil RW. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246:502-509; discussion 509. [PMID: 17717454 DOI: 10.1097/sla.0b013e318148c704] [Cited by in Crossref: 331] [Cited by in F6Publishing: 103] [Article Influence: 22.1] [Reference Citation Analysis]
453 Das T, Diamond DL, Yeh M, Hassan S, Bryan JT, Reyes JD, Perkins JD. Molecular Signatures of Recurrent Hepatocellular Carcinoma Secondary to Hepatitis C Virus following Liver Transplantation. J Transplant 2013;2013:878297. [PMID: 24377043 DOI: 10.1155/2013/878297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
454 Hagihara A, Ikeda M, Ueno H, Morizane C, Kondo S, Nakachi K, Mitsunaga S, Shimizu S, Kojima Y, Suzuki E, Katayama K, Imanaka K, Tamai C, Inaba Y, Sato Y, Kato M, Okusaka T. Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma. Cancer Sci 2014;105:354-8. [PMID: 24438504 DOI: 10.1111/cas.12353] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
455 Chew V, Tow C, Huang C, Bard-Chapeau E, Copeland NG, Jenkins NA, Weber A, Lim KH, Toh HC, Heikenwalder M. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst. 2012;104:1796-1807. [PMID: 23197495 DOI: 10.1093/jnci/djs436] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 5.9] [Reference Citation Analysis]
456 He W, Zeng Q, Zheng Y, Chen M, Shen J, Qiu J, Zou R, Liao Y, Li Q, Wu X, Li B, Yuan Y. The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis. BMC Cancer. 2015;15:263. [PMID: 25886495 DOI: 10.1186/s12885-015-1280-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
457 Lu CX, Nan KJ, Nie YL, Hai YN, Jiao M. Delisheng, a Chinese medicinal compound, exerts anti-proliferative and pro-apoptotic effects on HepG2 cells through extrinsic and intrinsic pathways. Mol Biol Rep 2010;37:3407-12. [PMID: 20012371 DOI: 10.1007/s11033-009-9930-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
458 Cai E, Song X, Han M, Yang L, Zhao Y, Li W, Han J, Tu S. Experimental study of the anti-tumour activity and pharmacokinetics of arctigenin and its valine ester derivative. Sci Rep 2018;8:3307. [PMID: 29459629 DOI: 10.1038/s41598-018-21722-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
459 Li GM, Liang CJ, Zhang DX, Zhang LJ, Wu JX, Xu YC. XB130 Knockdown Inhibits the Proliferation, Invasiveness, and Metastasis of Hepatocellular Carcinoma Cells and Sensitizes them to TRAIL-Induced Apoptosis. Chin Med J (Engl) 2018;131:2320-31. [PMID: 30246718 DOI: 10.4103/0366-6999.241800] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
460 Abdel-Hamid NM, Abdel-Ghany MI, Nazmy MH, Amgad SW. Can methanolic extract of Nigella sativa seed affect glyco-regulatory enzymes in experimental hepatocellular carcinoma? Environ Health Prev Med 2013;18:49-56. [PMID: 22767221 DOI: 10.1007/s12199-012-0292-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
461 Zhang ZF, Luo YJ, Lu Q, Dai SX, Sha WH. Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new? World J Clin Cases 2018; 6(9): 259-273 [PMID: 30211206 DOI: 10.12998/wjcc.v6.i9.259] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
462 Thng CH, Kuo YT. Hepatocellular carcinoma - issues in imaging. Cancer Imaging 2004;4:174-80. [PMID: 18250027 DOI: 10.1102/1470-7330.2004.0063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
463 Erinjeri JP, Salhab HM, Covey AM, Getrajdman GI, Brown KT. Arterial patency after repeated hepatic artery bland particle embolization. J Vasc Interv Radiol. 2010;21:522-526. [PMID: 20188589 DOI: 10.1016/j.jvir.2009.12.390] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
464 Turati F, Talamini R, Pelucchi C, Polesel J, Franceschi S, Crispo A, Izzo F, La Vecchia C, Boffetta P, Montella M. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer 2013;108:222-8. [PMID: 23169288 DOI: 10.1038/bjc.2012.492] [Cited by in Crossref: 93] [Cited by in F6Publishing: 80] [Article Influence: 9.3] [Reference Citation Analysis]
465 Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res. 2013;43:147-154. [PMID: 23145926 DOI: 10.1111/j.1872-034x.2012.01113] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
466 Motawi TK, Shaker OG, El-Maragh SA, Senousy MA. Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients. PLOS One. 2015;10:e0137706. [PMID: 26352740 DOI: 10.1371/journal.pone.0137706] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 7.1] [Reference Citation Analysis]
467 Lin CC, Zhou JP, Liu YP, Liu JJ, Yang XN, Jazag A, Zhang ZP, Guleng B, Ren JL. The silencing of Pokemon attenuates the proliferation of hepatocellular carcinoma cells in vitro and in vivo by inhibiting the PI3K/Akt pathway. PLoS One 2012;7:e51916. [PMID: 23300578 DOI: 10.1371/journal.pone.0051916] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
468 Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013;144:1024-30. [PMID: 23333348 DOI: 10.1053/j.gastro.2013.01.021] [Cited by in Crossref: 125] [Cited by in F6Publishing: 121] [Article Influence: 13.9] [Reference Citation Analysis]
469 Miyamoto N, Hiramatsu K, Tsuchiya K, Sato Y. Carbon dioxide microbubbles-enhanced sonographically guided radiofrequency ablation: treatment of patients with local progression of hepatocellular carcinoma. Radiat Med. 2008;26:92-97. [PMID: 18301986 DOI: 10.1007/s11604-007-0198-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
470 Makpol S, Yaacob N, Zainuddin A, Yusof YA, Ngah WZ. Chlorella vulgaris modulates hydrogen peroxide-induced DNA damage and telomere shortening of human fibroblasts derived from different aged individuals. Afr J Tradit Complement Altern Med 2009;6:560-72. [PMID: 20606778 DOI: 10.4314/ajtcam.v6i4.57210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
471 Zhang W, Song TQ, Zhang T, Wu Q, Kong DL, Li Q, Sun HC. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitis. Mol Clin Oncol. 2014;2:1125-1134. [PMID: 25279210 DOI: 10.3892/mco.2014.386] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
472 Xu C, Shi L, Chen W, Fang P, Li J, Jin L, Pan Z, Pan C. MiR-106b inhibitors sensitize TRAIL-induced apoptosis in hepatocellular carcinoma through increase of death receptor 4. Oncotarget 2017;8:41921-31. [PMID: 28410209 DOI: 10.18632/oncotarget.16707] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
473 Kudo M. A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion. Liver Cancer 2021;10:539-44. [PMID: 34950177 DOI: 10.1159/000519749] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
474 Ormandy LA, Färber A, Cantz T, Petrykowska S, Wedemeyer H, Hörning M, Lehner F, Manns MP, Korangy F, Greten TF. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol 2006; 12(20): 3275-3282 [PMID: 16718852 DOI: 10.3748/wjg.v12.i20.3275] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 58] [Article Influence: 4.1] [Reference Citation Analysis]
475 Chen J, Lai L, Lin Q, Huang W, Cai M, Zhu K, Huang M. Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study. Oncotarget 2017;8:408-17. [PMID: 27880724 DOI: 10.18632/oncotarget.13427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
476 Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408-424. [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103] [Cited by in Crossref: 260] [Cited by in F6Publishing: 261] [Article Influence: 37.1] [Reference Citation Analysis]
477 Mizuguchi Y, Mishima T, Yokomuro S, Arima Y, Kawahigashi Y, Shigehara K, Kanda T, Yoshida H, Uchida E, Tajiri T. Sequencing and bioinformatics-based analyses of the microRNA transcriptome in hepatitis B-related hepatocellular carcinoma. PLoS One. 2011;6:e15304. [PMID: 21283620 DOI: 10.1371/journal.pone.0015304] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
478 Chen S, Yu W, Zhang K, Liu W, Chen Q. Transarterial chemoembolization for unresectable hepatocellular carcinoma: A comparison of the efficacy and safety of 2 embolic agents. Medicine (Baltimore) 2018;97:e10832. [PMID: 29794774 DOI: 10.1097/MD.0000000000010832] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
479 Shinoda M, Kishida N, Itano O, Ei S, Ueno A, Kitago M, Abe Y, Hibi T, Yagi H, Masugi Y. Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature. World J Surg Oncol. 2015;13:144. [PMID: 25889667 DOI: 10.1186/s12957-015-0559-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
480 Wang S, Zhu Y, He H, Liu J, Xu L, Zhang H, Liu H, Liu W, Liu Y, Pan D, Chen L, Wu Q, Xu J, Gu J. Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2. Cancer Sci 2013;104:750-9. [PMID: 23421437 DOI: 10.1111/cas.12132] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
481 Liu X, Zou L, Liu F, Zhou Y, Song B. Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8:e70896. [PMID: 23967130 DOI: 10.1371/journal.pone.0070896] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
482 Zhao J, Chen J, Lin H, Jin R, Liu J, Liu X, Meng N, Cai X. The Clinicopathologic Significance of BAF250a (ARID1A) Expression in Hepatocellular Carcinoma. Pathol Oncol Res. 2016;22:453-459. [PMID: 26589513 DOI: 10.1007/s12253-015-0022-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
483 Qu L, Wang Y, Gong L, Zhu J, Gong R, Si J. Suicide gene therapy for hepatocellular carcinoma cells by survivin promoter-driven expression of the herpes simplex virus thymidine kinase gene. Oncol Rep 2013;29:1435-40. [PMID: 23354806 DOI: 10.3892/or.2013.2248] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
484 Karanicolas PJ, Ko YJ. Transarterial Therapy for Primary Liver Carcinomas: A Crack in the Armor? Ann Surg Oncol 2015;22:4111-2. [PMID: 26228107 DOI: 10.1245/s10434-015-4776-9] [Reference Citation Analysis]
485 Xu LB, Wang J, Liu C, Pang HW, Chen YJ, Ou QJ, Chen JS. Staging systems for predicting survival of patients with hepatocellular carcinoma after surgery. World J Gastroenterol 2010; 16(41): 5257-5262 [PMID: 21049561 DOI: 10.3748/wjg.v16.i41.5257] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
486 Eltawil KM, Kidd M, Giovinazzo F, Helmy AH, Salem RR. Differentiating the impact of anatomic and non-anatomic liver resection on early recurrence in patients with Hepatocellular Carcinoma. World J Surg Oncol 2010;8:43. [PMID: 20497548 DOI: 10.1186/1477-7819-8-43] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
487 Wang K, Mao Z, Liu L, Zhang R, Liang Q, Xiong Y, Yuan W, Wei L. Rab17 inhibits the tumourigenic properties of hepatocellular carcinomas via the Erk pathway. Tumour Biol 2015;36:5815-24. [PMID: 25707355 DOI: 10.1007/s13277-015-3251-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
488 Alberts SR, Fitch TR, Kim GP, Morlan BW, Dakhil SR, Gross HM, Nair S. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial. Am J Clin Oncol. 2012;35:329-333. [PMID: 21422991 DOI: 10.1097/coc.0b013e3182118cdf] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
489 Peveling-Oberhag J, Seiz A, Döring C, Hartmann S, Köberle V, Liese J, Zeuzem S, Hansmann ML, Piiper A. MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule. Transl Oncol 2014;7:672-80. [PMID: 25500075 DOI: 10.1016/j.tranon.2014.09.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
490 Lee S, Yoon SH, Park JY, Kim DY, Ahn SH, Han K, Choi HJ. Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. Invest New Drugs 2012;30:1150-7. [DOI: 10.1007/s10637-011-9634-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
491 Braunwarth E, Stättner S, Fodor M, Cardini B, Resch T, Oberhuber R, Putzer D, Bale R, Maglione M, Margreiter C, Schneeberger S, Öfner D, Primavesi F. Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma. Eur Surg 2018;50:100-12. [PMID: 29875798 DOI: 10.1007/s10353-018-0537-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
492 Yoon AR, Hong J, Kim M, Yun CO. Hepatocellular carcinoma-targeting oncolytic adenovirus overcomes hypoxic tumor microenvironment and effectively disperses through both central and peripheral tumor regions. Sci Rep 2018;8:2233. [PMID: 29396500 DOI: 10.1038/s41598-018-20268-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
493 Shirabe K, Mano Y, Muto J, Matono R, Motomura T, Toshima T, Takeishi K, Uchiyama H, Yoshizumi T, Taketomi A, Morita M, Tsujitani S, Sakaguchi Y, Maehara Y. Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surg Today 2012;42:1-7. [DOI: 10.1007/s00595-011-0058-8] [Cited by in Crossref: 97] [Cited by in F6Publishing: 95] [Article Influence: 8.8] [Reference Citation Analysis]
494 Lee S, Kim BK, Kim SU, Park JY, Kim do Y, Ahn SH, Han KH. Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. J Hepatocell Carcinoma 2015;2:39-47. [PMID: 27508193 DOI: 10.2147/JHC.S79353] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
495 Xia F, Lau WY, Xu Y, Wu L, Qian C, Bie P. Does hepatic ischemia-reperfusion injury induced by hepatic pedicle clamping affect survival after partial hepatectomy for hepatocellular carcinoma? World J Surg. 2013;37:192-201. [PMID: 22965538 DOI: 10.1007/s00268-012-1781-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
496 Nadarevic T, Colli A, Giljaca V, Fraquelli M, Casazza G, Manzotti C, Štimac D, Miletic D. Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2022;5:CD014798. [PMID: 35521901 DOI: 10.1002/14651858.CD014798.pub2] [Reference Citation Analysis]
497 Lin LT, Wu SJ, Lin CC. The Anticancer Properties and Apoptosis-inducing Mechanisms of Cinnamaldehyde and the Herbal Prescription Huang-Lian-Jie-Du-Tang ( Huáng Lián Jiě Dú Tang) in Human Hepatoma Cells. J Tradit Complement Med 2013;3:227-33. [PMID: 24716182 DOI: 10.4103/2225-4110.119732] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
498 Gupta N, Verma RK, Prinja S, Dhiman RK. Cost-effectiveness of Sorafenib for Treatment of Advanced Hepatocellular Carcinoma in India. J Clin Exp Hepatol 2019;9:468-75. [PMID: 31516263 DOI: 10.1016/j.jceh.2018.10.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
499 Biondi A, Malaguarnera G, Vacante M, Berretta M, D’Agata V, Malaguarnera M, Basile F, Drago F, Bertino G. Elevated serum levels of Chromogranin A in hepatocellular carcinoma. BMC Surg. 2012;12 Suppl 1:S7. [PMID: 23173843 DOI: 10.1186/1471-2482-12-s1-s7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
500 Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2014;68:609-17. [PMID: 24283303 DOI: 10.1111/ijcp.12352] [Cited by in Crossref: 154] [Cited by in F6Publishing: 140] [Article Influence: 17.1] [Reference Citation Analysis]
501 Rosen MD, Privalsky ML. Thyroid hormone receptor mutations in cancer and resistance to thyroid hormone: perspective and prognosis. J Thyroid Res 2011;2011:361304. [PMID: 21760978 DOI: 10.4061/2011/361304] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
502 Gao XD, Qu JH, Chang XJ, Lu YY, Bai WL, Wang H, Xu ZX, An LJ, Wang CP, Zeng Z, Yang YP. Hypomethylation of long interspersed nuclear element-1 promoter is associated with poor outcomes for curative resected hepatocellular carcinoma. Liver Int 2014;34:136-46. [PMID: 23875825 DOI: 10.1111/liv.12264] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
503 Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009; 15(11): 1301-1314 [PMID: 19294759 DOI: 10.3748/wjg.15.1301] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 87] [Article Influence: 8.0] [Reference Citation Analysis]
504 Fok AJ, She WH, Ma KW, Tsang SHY, Dai WC, Chan ACY, Lo CM, Cheung TT. Adjuvant transarterial chemotherapy for margin-positive resection of hepatocellular carcinoma-a propensity score matched analysis. Langenbecks Arch Surg 2021. [PMID: 34406489 DOI: 10.1007/s00423-021-02292-9] [Reference Citation Analysis]
505 Mahnken AH, Bruners P, Günther RW. Techniques of interventional tumor therapy. Dtsch Arztebl Int 2008;105:646-53. [PMID: 19471636 DOI: 10.3238/arztebl.2008.0646] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
506 Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Uesaka K. The optimal cut-off value of the preoperative prognostic nutritional index for the survival differs according to the TNM stage in hepatocellular carcinoma. Surg Today 2017;47:986-93. [PMID: 28315008 DOI: 10.1007/s00595-017-1491-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
507 Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135:1972-1983, 1983.e1-1983.11. [PMID: 18929564 DOI: 10.1053/j.gastro.2008.08.008] [Cited by in Crossref: 482] [Cited by in F6Publishing: 479] [Article Influence: 34.4] [Reference Citation Analysis]
508 Zhou S, Han Q, Wang R, Li X, Wang Q, Wang H, Wang J, Ma Y. PRDX2 protects hepatocellular carcinoma SMMC-7721 cells from oxidative stress. Oncol Lett 2016;12:2217-21. [PMID: 27602166 DOI: 10.3892/ol.2016.4899] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
509 Wu C, Gong F, Pang P, Shen M, Zhu K, Cheng D, Liu Z, Shan H. An RGD-modified MRI-visible polymeric vector for targeted siRNA delivery to hepatocellular carcinoma in nude mice. PLoS One. 2013;8:e66416. [PMID: 23922634 DOI: 10.1371/journal.pone.0066416] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
510 Zhu Q, Li N, Li F, Zhou Z, Sang J, Zeng X, Han Q, Lv Y, Zhao W, Liu Z. How admissions to various medical specialty divisions determines the outcome of patients with hepatocellular carcinoma: results from a retrospective study in a large hospital of northwest China. Ther Clin Risk Manag 2017;13:545-53. [PMID: 28458557 DOI: 10.2147/TCRM.S131290] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
511 Chen CT, Liao LZ, Lu CH, Huang YH, Lin YK, Lin JH, Chow LP. Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells. Exp Mol Med 2020;52:497-513. [PMID: 32203105 DOI: 10.1038/s12276-020-0404-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
512 Ding YT. Research progress of liver resection for hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2009; 17(10): 955-961 [DOI: 10.11569/wcjd.v17.i10.955] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
513 Ling YH, Chen JW, Wen SH, Huang CY, Li P, Lu LH, Mei J, Li SH, Wei W, Cai MY, Guo RP. Tumor necrosis as a poor prognostic predictor on postoperative survival of patients with solitary small hepatocellular carcinoma. BMC Cancer 2020;20:607. [PMID: 32600297 DOI: 10.1186/s12885-020-07097-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
514 Loomba R, Liu J, Yang HI, Lee MH, Lu SN, Wang LY, Iloeje UH, You SL, Brenner D, Chen CJ; REVEAL–HBV Study Group. Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol 2013;11:1636-45.e1-3. [PMID: 23669307 DOI: 10.1016/j.cgh.2013.04.043] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
515 Kato Y, Okamura Y, Omae K, Sugiura T, Ito T, Yamamoto Y, Ashida R, Sato R, Aramaki T, Uesaka K. Propensity score-matched comparison of non-anatomical resection and radiofrequency ablation for hepatocellular carcinoma in patients with up to three tumours, each measuring up to 3 cm in diameter. BJS Open 2018;2:213-9. [PMID: 30079390 DOI: 10.1002/bjs5.60] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
516 Wang Y, Speeg KV, Washburn WK, Halff G. Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report. World J Gastroenterol 2010; 16(43): 5518-5522 [PMID: 21086573 DOI: 10.3748/wjg.v16.i43.5518] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
517 Feng Q, Chi Y, Liu Y, Zhang L, Liu Q. Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studies. J Cancer Res Clin Oncol 2015;141:1-9. [PMID: 24889505 DOI: 10.1007/s00432-014-1708-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
518 Tian Y, Lyu H, He Y, Kanduri HK. Evaluating the Ability of the New Subclassification to Prognosticate Outcomes Following Hepatectomy for Patients with HBV-Related HCC. J Gastrointest Cancer 2019;50:400-7. [PMID: 29512001 DOI: 10.1007/s12029-018-0085-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
519 Harnois DM. Hepatitis C virus infection and the rising incidence of hepatocellular carcinoma. Mayo Clin Proc. 2012;87:7-8. [PMID: 22212962 DOI: 10.1016/j.mayocp.2011.11.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
520 Matsuda Y, Ichida T, Fukumoto M. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol 2011;44:117-24. [PMID: 21922382 DOI: 10.1007/s00795-011-0547-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
521 Hamilton JP. Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignancies. Epigenomics 2010;2:233-43. [PMID: 20556199 DOI: 10.2217/epi.10.9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
522 Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S, Lowe SW. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006;125:1253-1267. [PMID: 16814713 DOI: 10.1016/j.cell.2006.05.030] [Cited by in Crossref: 774] [Cited by in F6Publishing: 766] [Article Influence: 48.4] [Reference Citation Analysis]
523 Costa FP, de Oliveira AC, Meirelles R, Machado MC, Zanesco T, Surjan R, Chammas MC, de Souza Rocha M, Morgan D, Cantor A, Zimmerman J, Brezovich I, Kuster N, Barbault A, Pasche B. Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. Br J Cancer 2011;105:640-8. [PMID: 21829195 DOI: 10.1038/bjc.2011.292] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
524 Yousef MI, Refaat MM, Faheem MH. Role of diffusion-weighted magnetic resonance imaging in the evaluation of hepatocellular carcinoma response to transcatheter arterial chemoembolization using drug eluting beads; correlation with dynamic MRI. The Egyptian Journal of Radiology and Nuclear Medicine 2017;48:817-24. [DOI: 10.1016/j.ejrnm.2017.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
525 Fan J, Zhou J, Wu ZQ, Qiu SJ, Wang XY, Shi YH, Tang ZY. Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2005; 11(8): 1215-1219 [PMID: 15754408 DOI: 10.3748/wjg.v11.i8.1215] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 50] [Article Influence: 2.9] [Reference Citation Analysis]
526 Jehan S, Zhong C, Li G, Zulqarnain Bakhtiar S, Li D, Sui G. Thymoquinone Selectively Induces Hepatocellular Carcinoma Cell Apoptosis in Synergism With Clinical Therapeutics and Dependence of p53 Status. Front Pharmacol. 2020;11:555283. [PMID: 33041795 DOI: 10.3389/fphar.2020.555283] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
527 Lu J, Xu L, Zou Y, Yang RX, Fan Y, Zhang W, Yu D, Yao YG. IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma. Med Sci Monit 2014;20:247-54. [PMID: 24531386 DOI: 10.12659/MSM.889891] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
528 Enooku K, Uranbileg B, Ikeda H, Kurano M, Sato M, Kudo H, Maki H, Koike K, Hasegawa K, Kokudo N, Yatomi Y. Higher LPA2 and LPA6 mRNA Levels in Hepatocellular Carcinoma Are Associated with Poorer Differentiation, Microvascular Invasion and Earlier Recurrence with Higher Serum Autotaxin Levels. PLoS One 2016;11:e0161825. [PMID: 27583415 DOI: 10.1371/journal.pone.0161825] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
529 Chow PK, Choo SP, Ng DC, Lo RH, Wang ML, Toh HC, Tai DW, Goh BK, Wong JS, Tay KH, Goh AS, Yan SX, Loke KS, Thang SP, Gogna A, Too CW, Irani FG, Leong S, Lim KH, Thng CH. National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. Liver Cancer. 2016;5:97-106. [PMID: 27386428 DOI: 10.1159/000367759] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
530 Levi Sandri GB, Colasanti M, Santoro R, Ettorre GM. Laparoscopic right hepatectomy for hepatocellular carcinoma in cirrhotic patient. Hepatobiliary Surg Nutr 2015;4:436-8. [PMID: 26734630 DOI: 10.3978/j.issn.2304-3881.2015.07.01] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
531 Yen YH, Li WF, Kee KM, Wang CC, Cheng YF, Wang JH, Lu SN, Hung CH. The characteristics of patients with macrovascular invasion in hepatocellular carcinoma: when East meets West. Langenbecks Arch Surg 2021. [PMID: 34825277 DOI: 10.1007/s00423-021-02370-y] [Reference Citation Analysis]
532 Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6-25. [PMID: 17103105 DOI: 10.1007/s00270-006-0062-3] [Cited by in Crossref: 564] [Cited by in F6Publishing: 526] [Article Influence: 37.6] [Reference Citation Analysis]
533 Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, Rodriguez-Carunchio L, Solé M, Thung S, Stanger BZ. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology. 2012;143:1660-1669.e7. [PMID: 22974708 DOI: 10.1053/j.gastro.2012.09.002] [Cited by in Crossref: 193] [Cited by in F6Publishing: 185] [Article Influence: 19.3] [Reference Citation Analysis]
534 Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212. [PMID: 15887976 DOI: 10.2165/00066982-200408040-00002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
535 Andersen JB, Loi R, Perra A, Factor VM, Ledda-Columbano GM, Columbano A, Thorgeirsson SS. Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology. 2010;51:1401-1409. [PMID: 20054870 DOI: 10.1002/hep.23488] [Cited by in Crossref: 95] [Cited by in F6Publishing: 99] [Article Influence: 7.9] [Reference Citation Analysis]
536 Gomaa AI, Al-Khatib A, Abdel-Razek W, Hashim MS, Waked I. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging. World J Gastroenterol 2015; 21(18): 5654-5662 [PMID: 25987792 DOI: 10.3748/wjg.v21.i18.5654] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
537 Zhang QY, Chen H, Lin Z, Lin JM. Comparison of chemiluminescence enzyme immunoassay based on magnetic microparticles with traditional colorimetric ELISA for the detection of serum α-fetoprotein. J Pharm Anal 2012;2:130-5. [PMID: 29403732 DOI: 10.1016/j.jpha.2011.10.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
538 Rabelo-Gonçalves EM, Roesler BM, Zeitune JM. Extragastric manifestations of Helicobacter pylori infection: Possible role of bacterium in liver and pancreas diseases. World J Hepatol 2015; 7(30): 2968-2979 [PMID: 26730276 DOI: 10.4254/wjh.v7.i30.2968] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
539 Yang H, Zheng W, Shuai X, Chang RM, Yu L, Fang F, Yang LY. MicroRNA-424 inhibits Akt3/E2F3 axis and tumor growth in hepatocellular carcinoma. Oncotarget 2015;6:27736-50. [PMID: 26315541 DOI: 10.18632/oncotarget.4811] [Cited by in Crossref: 33] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
540 Hu Z, Li Z, Xiang J, Zhou J, Yan S, Wu J, Zhou L, Zheng S. Intent-to-treat analysis of liver transplant for hepatocellular carcinoma in the MELD era: impact of hepatitis C and advanced status. Dig Dis Sci 2014;59:3062-72. [PMID: 25008426 DOI: 10.1007/s10620-014-3266-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
541 Macdonald DC, Nelson M, Bower M, Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol 2008; 14(11): 1657-1663 [PMID: 18350596 DOI: 10.3748/wjg.14.1657] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
542 Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N, Nishikaku F. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2009;64:473-483. [PMID: 19104812 DOI: 10.1007/s00280-008-0895-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
543 Qu LS, Liu JX, Liu TT, Shen XZ, Chen TY, Ni ZP, Lu CH. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in Qidong, China. PLoS One. 2014;9:e98257. [PMID: 24849936 DOI: 10.1371/journal.pone.0098257] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
544 Song JM, Lu M, Liu FF, Du XJ, Xing BC. AIB1 as an independent prognostic marker in hepatocellular carcinoma after hepatic resection. J Gastrointest Surg 2012;16:356-60. [PMID: 22052107 DOI: 10.1007/s11605-011-1762-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
545 Yang H, Nie Y, Li Y, Wan YJ. Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells. Exp Biol Med (Maywood) 2010;235:32-9. [PMID: 20404016 DOI: 10.1258/ebm.2009.009252] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
546 Belghiti J, Fuks D. Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer. 2012;1:71-82. [PMID: 24159575 DOI: 10.1159/00034240] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
547 Chiou HE, Wang TE, Wang YY, Liu HW. Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. World J Gastroenterol 2006; 12(43): 6955-6960 [PMID: 17109516 DOI: 10.3748/wjg.v12.i43.6955] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
548 Lee JS, Kim JH, Park YY, Mills GB. Systems biology approaches to decoding the genome of liver cancer. Cancer Res Treat 2011;43:205-11. [PMID: 22247704 DOI: 10.4143/crt.2011.43.4.205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
549 Ofuji K, Saito K, Suzuki S, Shimomura M, Shirakawa H, Nobuoka D, Sawada Y, Yoshimura M, Tsuchiya N, Takahashi M, Yoshikawa T, Tada Y, Konishi M, Takahashi S, Gotohda N, Nakamoto Y, Nakatsura T. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma. Oncotarget 2017;8:37835-44. [PMID: 28035063 DOI: 10.18632/oncotarget.14271] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
550 Zhao GS, Liu Y, Zhang Q, Li C, Zhang YW, Ren ZZ, Zhou J, Zhang M. Transarterial chemoembolization combined with Huaier granule for the treatment of primary hepatic carcinoma: Safety and efficacy. Medicine (Baltimore) 2017;96:e7589. [PMID: 28723799 DOI: 10.1097/MD.0000000000007589] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
551 Bednarsch J, Czigany Z, Heise D, Joechle K, Luedde T, Heij L, Bruners P, Ulmer TF, Neumann UP, Lang SA. Prognostic evaluation of HCC patients undergoing surgical resection: an analysis of 8 different staging systems. Langenbecks Arch Surg. 2021;406:75-86. [PMID: 33294952 DOI: 10.1007/s00423-020-02052-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
552 Zhang F, Wang Y, Chen G, Li Z, Xing X, Putz-Bankuti C, Stauber RE, Liu X, Madl T. Growing Human Hepatocellular Tumors Undergo a Global Metabolic Reprogramming. Cancers (Basel) 2021;13:1980. [PMID: 33924061 DOI: 10.3390/cancers13081980] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
553 Mizuguchi T, Kawamoto M, Meguro M, Nakamura Y, Harada K, Kukita K, Hirata K. Prognostic impact of preoperative the branched-chain amino acid to the tyrosine ratio in hepatocellular carcinoma patients after initial hepatectomy. J Gastrointest Surg. 2011;15:1433-1439. [PMID: 21607795 DOI: 10.1007/s11605-011-1566-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
554 Hu JS, Wu DW, Liang S, Miao XY. GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol. 2010;27:339-345. [PMID: 19399652 DOI: 10.1007/s12032-009-9215-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
555 Chen HY, Han ZB, Fan JW, Xia J, Wu JY, Qiu GQ, Tang HM, Peng ZH. miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver. Med Oncol. 2012;29:1859-1865. [PMID: 21786180 DOI: 10.1007/s12032-011-0031-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
556 Bengochea A, de Souza MM, Lefrançois L, Le Roux E, Galy O, Chemin I, Kim M, Wands JR, Trepo C, Hainaut P. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer. 2008;99:143-150. [PMID: 18577996 DOI: 10.1038/sj.bjc.6604422] [Cited by in Crossref: 136] [Cited by in F6Publishing: 134] [Article Influence: 9.7] [Reference Citation Analysis]
557 Zou Y, Xiong H, Xiong H, Lu T, Zhu F, Luo Z, Yuan X, Wang Y. A polysaccharide from mushroom Huaier retards human hepatocellular carcinoma growth, angiogenesis, and metastasis in nude mice. Tumour Biol 2015;36:2929-36. [PMID: 25492485 DOI: 10.1007/s13277-014-2923-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
558 Liu Y, Zhang A, Liu Y, Dong J. Association analysis between the c.1804C>A genetic polymorphism of XRCC1 gene and risk of hepatocellular carcinoma in Chinese population. Med Oncol 2014;31:854. [PMID: 24526467 DOI: 10.1007/s12032-014-0854-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
559 Shields A, Reddy KR. Hepatocellular carcinoma: current treatment strategies. Curr Treat Options Gastroenterol 2005;8:457-66. [PMID: 16313863 DOI: 10.1007/s11938-005-0032-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
560 Reiter FP, Hadjamu NJ, Nagdyman N, Zachoval R, Mayerle J, De Toni EN, Kaemmerer H, Denk G. Congenital heart disease-associated liver disease: a narrative review. Cardiovasc Diagn Ther 2021;11:577-90. [PMID: 33968635 DOI: 10.21037/cdt-20-595] [Reference Citation Analysis]
561 Xu Y, Chenna V, Hu C, Sun HX, Khan M, Bai H, Yang XR, Zhu QF, Sun YF, Maitra A. Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res. 2012;18:1291-1302. [PMID: 21868763 DOI: 10.1158/1078-0432.CCR-11-0950] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
562 Helmberger T, Hoffmann RT, Jakobs T, Leibecke T, Lubienski A, Reiser M. [Liver tumor ablation]. Radiologe. 2005;45:55-62. [PMID: 15609015 DOI: 10.1007/s00117-004-1149-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
563 Chen YY, Zhang XN, Xu CZ, Zhou DH, Chen J, Liu ZX, Sun Y, Huang W, Qu LS. MCCC2 promotes HCC development by supporting leucine oncogenic function. Cancer Cell Int 2021;21:22. [PMID: 33407468 DOI: 10.1186/s12935-020-01722-w] [Reference Citation Analysis]
564 Kern MA, Breuhahn K, Schuchmann M, Schirmacher P. [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology]. Pathologe 2007;28:261-8. [PMID: 17605064 DOI: 10.1007/s00292-007-0890-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
565 Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Marsh JW, Martignetti JA, Llovet JM. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol. 2008;49:581-588. [PMID: 18602719 DOI: 10.1016/j.jhep.2008.03.032] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 4.4] [Reference Citation Analysis]
566 Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, Conner EA, Thorgeirsson SS. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med 2010;2:54ra77. [PMID: 20962331 DOI: 10.1126/scitranslmed.3001338] [Cited by in Crossref: 62] [Cited by in F6Publishing: 69] [Article Influence: 5.6] [Reference Citation Analysis]
567 Pan WD, Zheng RQ, Nan L, Fang HP, Liu B, Tang ZF, Deng MH, Xu RY. Ultrasound-guided percutaneous microwave coagulation therapy with a “cooled-tip needle” for the treatment of hepatocellular carcinoma adjacent to the gallbladder. Dig Dis Sci. 2010;55:2664-2669. [PMID: 19949862 DOI: 10.1007/s10620-009-1053-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
568 Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirrmacher P, Schmidt J, Büchler MW. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer. 2008;8:349. [PMID: 19036146 DOI: 10.1186/1471-2407-8-3491471-2407-8-349] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
569 Zhou F, Hu J, Shao JH, Zou SB, Shen SL, Luo ZQ. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol 2012;138:1879-90. [PMID: 22736027 DOI: 10.1007/s00432-012-1270-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
570 Geier A, Macias RI, Bettinger D, Weiss J, Bantel H, Jahn D, Al-Abdulla R, Marin JJ. The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. Oncotarget 2017;8:15846-57. [PMID: 28178663 DOI: 10.18632/oncotarget.15029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
571 Guo C, Liu S, Sun MZ. Novel insight into the role of GAPDH playing in tumor. Clin Transl Oncol. 2013;15:167-172. [PMID: 22911551 DOI: 10.1007/s12094-012-0924-x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 6.0] [Reference Citation Analysis]
572 Cao J, Zhao M, Liu J, Zhang X, Pei Y, Wang J, Yang X, Shen B, Zhang J. RACK1 Promotes Self-Renewal and Chemoresistance of Cancer Stem Cells in Human Hepatocellular Carcinoma through Stabilizing Nanog. Theranostics 2019;9:811-28. [PMID: 30809310 DOI: 10.7150/thno.29271] [Cited by in Crossref: 16] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
573 Chen J, Lu S, Zhang Y, Xu L, Chen J, Wang J, Chen M, Zhang R, Zhou Z. Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis. J Cancer. 2018;9:1745-1753. [PMID: 29805700 DOI: 10.7150/jca.24568] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
574 Tonon F, Farra R, Zennaro C, Pozzato G, Truong N, Parisi S, Rizzolio F, Grassi M, Scaggiante B, Zanconati F, Bonazza D, Grassi G, Dapas B. Xenograft Zebrafish Models for the Development of Novel Anti-Hepatocellular Carcinoma Molecules. Pharmaceuticals (Basel) 2021;14:803. [PMID: 34451900 DOI: 10.3390/ph14080803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
575 Guo X, Zhang W, Du J, Tao R, Dong W, Huang J, Zhang J, Pan Z, Zhou W, Zhu X, Liu H, Liu F. Acute-Phase Serum Amyloid A May Predict Microvascular Invasion and Early Tumor Recurrence in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Undergoing Liver Resection. J Invest Surg 2022;:1-9. [PMID: 35143736 DOI: 10.1080/08941939.2022.2035858] [Reference Citation Analysis]
576 Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology. 2008;47:2059-2067. [PMID: 18506891 DOI: 10.1002/hep.22283] [Cited by in Crossref: 227] [Cited by in F6Publishing: 228] [Article Influence: 16.2] [Reference Citation Analysis]
577 Xu W, Huang JJ, Cheung PC. Extract of Pleurotus pulmonarius suppresses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathway. PLoS One 2012;7:e34406. [PMID: 22470568 DOI: 10.1371/journal.pone.0034406] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
578 Liu N, Jiao T, Huang Y, Liu W, Li Z, Ye X. Hepatitis B virus regulates apoptosis and tumorigenesis through the microRNA-15a-Smad7-transforming growth factor beta pathway. J Virol. 2015;89:2739-2749. [PMID: 25540364 DOI: 10.1128/jvi.02784-14] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
579 Kudo M, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan. Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan. Liver Cancer 2016;5:190-7. [PMID: 27493894 DOI: 10.1159/000367775] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 9.5] [Reference Citation Analysis]
580 Hassan ZK, Hafez MM, Mansor TM, Zekri AR. Occult HBV infection among Egyptian hepatocellular carcinoma patients. Virol J. 2011;8:90. [PMID: 21371325 DOI: 10.1186/1743-422x-8-90] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
581 Liu CJ, Chang J, Lee PH, Lin DY, Wu CC, Jeng LB, Lin YJ, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Yang MD, Yu MC, Hu RH, Peng CY, Lai KL, Chang SSC, Chen PJ. Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World J Gastroenterol 2014; 20(32): 11384-11393 [PMID: 25170226 DOI: 10.3748/wjg.v20.i32.11384] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
582 Wang P, Wang C, Li H, Shi B, Wang J, Zhong L. Impact of age on the prognosis after liver transplantation for patients with hepatocellular carcinoma: a single-center experience. Onco Targets Ther 2015;8:3775-81. [PMID: 26719705 DOI: 10.2147/OTT.S93939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
583 Shi M, Chen JA, Lin XJ, Guo RP, Yuan YF, Chen MS, Zhang YQ, Li JQ. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World J Gastroenterol 2010; 16(2): 264-269 [PMID: 20066748 DOI: 10.3748/wjg.v16.i2.264] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
584 Paul SB, Gamanagatti S, Sreenivas V, Chandrashekhara SH, Mukund A, Gulati MS, Gupta AK, Acharya SK. Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: Experience from a tertiary care centre in India. Indian J Radiol Imaging. 2011;21:113-120. [PMID: 21799594 DOI: 10.4103/0971-3026.82294] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
585 Zhao YL, Guo QQ, Yang GR, Wang QD. Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma. J Zhejiang Univ Sci B. 2014;15:713-719. [PMID: 25091989 DOI: 10.1631/jzus.B1400010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
586 Zhong JH, You XM, Gong WF, Ma L, Zhang Y, Mo QG, Wu LC, Xiao J, Li LQ. Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: a meta-analysis. PLoS One 2012;7:e32159. [PMID: 22403631 DOI: 10.1371/journal.pone.0032159] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
587 Shen Y, Guo H, Wu T, Lu Q, Nan KJ, Lv Y, Zhang XF. Lower Education and Household Income Contribute to Advanced Disease, Less Treatment Received and Poorer Prognosis in Patients with Hepatocellular Carcinoma. J Cancer 2017;8:3070-7. [PMID: 28928898 DOI: 10.7150/jca.19922] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
588 Marquardt JU, Factor VM, Thorgeirsson SS. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol 2010;53:568-77. [PMID: 20646772 DOI: 10.1016/j.jhep.2010.05.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 5.5] [Reference Citation Analysis]
589 Takeuchi S, Rohren EM, Abdel-Wahab R, Xiao L, Morris JS, Macapinlac HA, Hassan MM, Kaseb AO. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. Eur J Nucl Med Mol Imaging 2017;44:969-78. [PMID: 27942837 DOI: 10.1007/s00259-016-3583-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
590 Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol. 2009;51:725-733. [PMID: 19665249 DOI: 10.1016/j.jhep.2009.03.028] [Cited by in Crossref: 160] [Cited by in F6Publishing: 146] [Article Influence: 12.3] [Reference Citation Analysis]
591 Hoffmann K, Xiao Z, Franz C, Mohr E, Serba S, Büchler MW, Schemmer P. Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro. Cancer Cell Int. 2011;11:40. [PMID: 22088142 DOI: 10.1186/1475-2867-11-40] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
592 Tanaka K, Takahashi Y, Wakabayashi T. An international expert consensus of management of recurrent hepatocellular carcinoma: a viewpoint. Hepatobiliary Surg Nutr 2020;9:394-6. [PMID: 32509840 DOI: 10.21037/hbsn.2019.10.23] [Reference Citation Analysis]
593 Yeh YC, Liu CJ, Kuo RN, Lai CL, Shau WY, Chen PJ, Lai MS. Association of adjuvant antiviral therapy with risk of cancer progression and deaths in patients with hepatitis-B-virus-related hepatocellular carcinoma following curative treatment: a nationwide cohort study. PLoS One. 2014;9:e102051. [PMID: 25025231 DOI: 10.1371/journal.pone.0102051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
594 Xu W, Kwon JH, Moon YH, Kim YB, Yu YS, Lee N, Choi KY, Kim YS, Park YK, Kim BW. Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2014;140:1507-1515. [PMID: 24853275 DOI: 10.1007/s00432-014-1713-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
595 Jiang W, Wang Z, Li X, Li J, Huang Y, Fan X, Duan Y. Reduced high-mobility group box 1 expression induced by RNA interference inhibits the bioactivity of hepatocellular carcinoma cell line HCCLM3. Dig Dis Sci. 2012;57:92-98. [PMID: 22038506 DOI: 10.1007/s10620-011-1944-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
596 Huang FY, Wong DK, Seto WK, Lai CL, Yuen MF. Estradiol induces apoptosis via activation of miRNA-23a and p53: implication for gender difference in liver cancer development. Oncotarget. 2015;6:34941-34952. [PMID: 26439986 DOI: 10.18632/oncotarget.5472] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
597 Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitsu H. Impact of more detailed categorization of shrinkage or progression ratio at initial imaging response after sorafenib treatment in advanced hepatocellular carcinoma patients. Onco Targets Ther 2015;8:3193-202. [PMID: 26586953 DOI: 10.2147/OTT.S94246] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
598 You MW, Kim SY, Kim KW, Lee SJ, Shin YM, Kim JH, Lee MG. Recent advances in the imaging of hepatocellular carcinoma. Clin Mol Hepatol. 2015;21:95-103. [PMID: 25834808 DOI: 10.3350/cmh.2015.21.1.95] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
599 Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF. [Therapy response of liver tumors after selective internal radiation therapy]. Radiologe. 2008;48:839-849. [PMID: 18766324 DOI: 10.1007/s00117-008-1730-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
600 Sonohara F, Yamada S, Tanaka N, Suenaga M, Takami H, Hayashi M, Niwa Y, Sugimoto H, Hattori N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y. Perioperative and prognostic implication of albumin-bilirubin-TNM score in Child-Pugh class A hepatocellular carcinoma. Ann Gastroenterol Surg. 2019;3:65-74. [PMID: 30697612 DOI: 10.1002/ags3.12212] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
601 Li D, Zeng Z. Epigenetic regulation of histone H3 in the process of hepatocellular tumorigenesis. Biosci Rep 2019;39:BSR20191815. [PMID: 31320544 DOI: 10.1042/BSR20191815] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
602 Gaudel P, Mohyuddin GR, Fields-Meehan J. Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients. Fed Pract 2021;38:89-91. [PMID: 33716486 DOI: 10.12788/fp.0061] [Reference Citation Analysis]
603 Utsunomiya T, Shimada M, Morine Y, Tajima A, Imoto I. Specific molecular signatures of non-tumor liver tissue may predict a risk of hepatocarcinogenesis. Cancer Sci 2014;105:749-54. [PMID: 24766251 DOI: 10.1111/cas.12431] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
604 Bi MR, Zhu LY, Yan BZ, Chen LY, Wang FX, Ma YJ, Yang BS. Association of Upregulated HMGB1 and c-IAP2 Proteins With Hepatocellular Carcinoma Development and Progression. Hepat Mon 2014;14:e23552. [PMID: 25685165 DOI: 10.5812/hepatmon.23552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
605 Chua CW, Choo SP. Targeted therapy in hepatocellular carcinoma. Int J Hepatol 2011;2011:348297. [PMID: 21994852 DOI: 10.4061/2011/348297] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
606 Polireddy K, Chavan H, Abdulkarim BA, Krishnamurthy P. Functional significance of the ATP-binding cassette transporter B6 in hepatocellular carcinoma. Mol Oncol 2011;5:410-25. [PMID: 21849266 DOI: 10.1016/j.molonc.2011.07.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
607 Prajapati HJ, Kim HS. Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization. PLoS One 2017;12:e0170750. [PMID: 28170405 DOI: 10.1371/journal.pone.0170750] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
608 Strassburg CP, Becker T, Klempnauer J, Manns MP. [Liver transplantation: deciding between need and donor allocation]. Internist (Berl) 2004;45:1233-45. [PMID: 15517126 DOI: 10.1007/s00108-004-1295-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
609 Oya H, Kanda M, Sugimoto H, Shimizu D, Takami H, Hibino S, Hashimoto R, Okamura Y, Yamada S, Fujii T. Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor. J Gastroenterol. 2015;50:590-600. [PMID: 25173447 DOI: 10.1007/s00535-014-0993-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
610 Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, Ouled-Haddou H, Ghamlouch H, Galmiche A, Chatelain D, Lamotte L, Debuysscher V, Fuentes V, Nguyen-Khac E, Regimbeau JM, Marolleau JP, Latour S, Bouhlal H. Identification of SLAMF3 (CD229) as an inhibitor of hepatocellular carcinoma cell proliferation and tumour progression. PLoS One 2013;8:e82918. [PMID: 24376606 DOI: 10.1371/journal.pone.0082918] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
611 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
612 Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, Štimac D. Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;10:CD013362. [PMID: 34611889 DOI: 10.1002/14651858.CD013362.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
613 Petruzziello A. Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma. Open Virol J. 2018;12:26-32. [PMID: 29541276 DOI: 10.2174/1874357901812010026] [Cited by in Crossref: 84] [Cited by in F6Publishing: 86] [Article Influence: 21.0] [Reference Citation Analysis]
614 Tsunedomi R, Yoshimura K, Kimura Y, Nishiyama M, Fujiwara N, Matsukuma S, Kanekiyo S, Matsui H, Shindo Y, Watanabe Y, Tokumitsu Y, Yoshida S, Iida M, Suzuki N, Takeda S, Ioka T, Hazama S, Nagano H. Elevated expression of RAB3B plays important roles in chemoresistance and metastatic potential of hepatoma cells. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09370-1] [Reference Citation Analysis]
615 Fan R, Miao Y, Shan X, Qian H, Song C, Wu G, Chen Y, Zha W. Bif-1 is overexpressed in hepatocellular carcinoma and correlates with shortened patient survival. Oncol Lett 2012;3:851-4. [PMID: 22741005 DOI: 10.3892/ol.2012.562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
616 Patterson AD, Maurhofer O, Beyoglu D, Lanz C, Krausz KW, Pabst T, Gonzalez FJ, Dufour JF, Idle JR. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res. 2011;71:6590-6600. [PMID: 21900402 DOI: 10.1158/0008-5472.can-11-0885] [Cited by in Crossref: 182] [Cited by in F6Publishing: 96] [Article Influence: 16.5] [Reference Citation Analysis]
617 She WH, Cheung TT. Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation. Transl Gastroenterol Hepatol. 2016;1:34. [PMID: 28138601 DOI: 10.21037/tgh.2016.03.04] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
618 Guo T, Gong C, Wu P, Battaglia-Hsu SF, Feng J, Liu P, Wang H, Guo D, Yao Y, Chen B, Xiao Y, Liu Z, Li Z. LINC00662 promotes hepatocellular carcinoma progression via altering genomic methylation profiles. Cell Death Differ 2020;27:2191-205. [PMID: 31959915 DOI: 10.1038/s41418-020-0494-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
619 Ma S, Yang J, Song C, Ge Z, Zhou J, Zhang G, Hu Z. Expression quantitative trait loci for PAX8 contributes to the prognosis of hepatocellular carcinoma. PLoS One 2017;12:e0173700. [PMID: 28339471 DOI: 10.1371/journal.pone.0173700] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
620 Wang D, Lu J, Liu Y, Meng Q, Xie J, Wang Z, Teng L. Liquiritigenin induces tumor cell death through mitogen-activated protein kinase- (MPAKs-) mediated pathway in hepatocellular carcinoma cells. Biomed Res Int 2014;2014:965316. [PMID: 24738081 DOI: 10.1155/2014/965316] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
621 Niu Y, Fan S, Luo Q, Chen L, Huang D, Chang W, Qin W, Shi G. Interaction of Hepatitis B Virus X Protein with the Pregnane X Receptor Enhances the Synergistic Effects of Aflatoxin B1 and Hepatitis B Virus on Promoting Hepatocarcinogenesis. J Clin Transl Hepatol 2021;9:466-76. [PMID: 34447675 DOI: 10.14218/JCTH.2021.00036] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
622 Pepin KM, Ehman RL, McGee KP. Magnetic resonance elastography (MRE) in cancer: Technique, analysis, and applications. Prog Nucl Magn Reson Spectrosc 2015;90-91:32-48. [PMID: 26592944 DOI: 10.1016/j.pnmrs.2015.06.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 5.6] [Reference Citation Analysis]
623 Pompili M, Nicolardi E, Abbate V, Miele L, Riccardi L, Covino M, Matthaeis ND, Grieco A, Landolfi R, Rapaccini GL. Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol 2011; 17(26): 3126-3132 [PMID: 21912455 DOI: 10.3748/wjg.v17.i26.3126] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
624 Jang SY, Kim G, Park SY, Lee YR, Kwon SH, Kim HS, Yoon JS, Lee JS, Kweon YO, Ha HT, Chun JM, Han YS, Lee WK, Chang JY, Park JG, Lee B, Tak WY, Hur K. Clinical significance of lncRNA-ATB expression in human hepatocellular carcinoma. Oncotarget. 2017;8:78588-78597. [PMID: 29108251 DOI: 10.18632/oncotarget.21094] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
625 Dai D, Xu W, Liu J, Zhu L, Zhu X, Ma X. Safety and efficacy of a peripheral intravenous bolus of Licartin for the treatment of advanced hepatocellular carcinoma. Exp Ther Med 2013;6:1417-22. [PMID: 24250722 DOI: 10.3892/etm.2013.1321] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
626 Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi H, Katsushima S, Kudo M, Takaguchi K, Hiasa Y, Chayama K, Yatsuhashi H, Oketani M, Kumada H. Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. J Gastroenterol 2013;48:382-90. [PMID: 22875473 DOI: 10.1007/s00535-012-0641-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
627 Squires MH, Hanish SI, Fisher SB, Garrett C, Kooby DA, Sarmiento JM, Cardona K, Adams AB, Russell MC, Magliocca JF. Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. J Surg Oncol. 2014;109:533-541. [PMID: 24347475 DOI: 10.1002/jso.23531] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
628 Park SC, Nguyen NT, Eun JR, Zhang Y, Jung YJ, Tschudy-Seney B, Trotsyuk A, Lam A, Ramsamooj R, Zhang Y, Theise ND, Zern MA, Duan Y. Identification of cancer stem cell subpopulations of CD34(+) PLC/PRF/5 that result in three types of human liver carcinomas. Stem Cells Dev 2015;24:1008-21. [PMID: 25519836 DOI: 10.1089/scd.2014.0405] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
629 Andersen KJ, Knudsen AR, Kannerup AS, Sasanuma H, Nyengaard JR, Hamilton-Dutoit S, Ladekarl M, Mortensen FV. Sorafenib inhibits liver regeneration in rats. HPB (Oxford) 2013;15:944-50. [PMID: 23461776 DOI: 10.1111/hpb.12068] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
630 Yang Y, Lu Y, Wang C, Bai W, Qu J, Chen Y, Chang X, An L, Zhou L, Zeng Z. Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. Cell Biochem Biophys. 2012;63:159-169. [PMID: 22477032 DOI: 10.1007/s12013-012-9353-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
631 Gluer AM, Cocco N, Laurence JM, Johnston ES, Hollands MJ, Pleass HC, Richardson AJ, Lam VW. Systematic review of actual 10-year survival following resection for hepatocellular carcinoma. HPB (Oxford). 2012;14:285-290. [PMID: 22487065 DOI: 10.1111/j.1477-2574.2012.00446.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 66] [Article Influence: 6.1] [Reference Citation Analysis]
632 Llovet JM, Lok A. Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1121-3. [PMID: 18695130 DOI: 10.1093/jnci/djn261] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
633 Zender L, Xue W, Cordón-Cardo C, Hannon GJ, Lucito R, Powers S, Flemming P, Spector MS, Lowe SW. Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb Symp Quant Biol. 2005;70:251-261. [PMID: 16869761 DOI: 10.1101/sqb.2005.70.059] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
634 Zhuang H, Peng YL, Chen TW, Jiang Y, Luo Y, Zhang Q, Yang ZG. The comparison of grey-scale ultrasonic and clinical features of hepatoblastoma and hepatocellular carcinoma in children: a retrospective study for ten years. BMC Gastroenterol 2011;11:78. [PMID: 21702993 DOI: 10.1186/1471-230X-11-78] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
635 Tsunematsu S, Muto S, Oi H, Naka T, Kitagataya T, Sasaki R, Taya Y, Baba U, Tsukamoto Y, Uemura K, Kimura T, Ohara Y. Surgically Diagnosed Primary Hepatic Angiosarcoma. Intern Med 2018;57:687-91. [PMID: 29151516 DOI: 10.2169/internalmedicine.9318-17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
636 Borzio M, Dionigi E, Rossini A, Toldi A, Francica G, Fornari F, Salmi A, Farinati F, Vicari S, Marignani M. Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an italian in-field experience. Dig Dis Sci. 2015;60:1465-1473. [PMID: 25399329 DOI: 10.1007/s10620-014-3427-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
637 Ribback S, Sailer V, Böhning E, Günther J, Merz J, Steinmüller F, Utpatel K, Cigliano A, Peters K, Pilo MG, Evert M, Calvisi DF, Dombrowski F. The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models. Int J Mol Sci 2016;17:E1618. [PMID: 27669229 DOI: 10.3390/ijms17101618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
638 Subat S, Mogushi K, Yasen M, Kohda T, Ishikawa Y, Tanaka H. Identification of genes and pathways, including the CXCL2 axis, altered by DNA methylation in hepatocellular carcinoma. J Cancer Res Clin Oncol 2019;145:675-84. [PMID: 30564899 DOI: 10.1007/s00432-018-2824-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
639 Wang ZX, Liu SL, Sun CH, Wang Q. Psychological intervention reduces postembolization pain during hepatic arterial chemoembolization therapy: A complementary approach to drug analgesia. World J Gastroenterol 2008; 14(6): 931-935 [PMID: 18240352 DOI: 10.3748/wjg.14.931] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
640 Li K, Wang HT, He YK, Guo T. New idea for treatment strategies for Barcelona Clinic Liver Cancer stages based on a network meta-analysis. Medicine (Baltimore) 2017;96:e6950. [PMID: 28514316 DOI: 10.1097/MD.0000000000006950] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
641 Bukhari S, Ward K, Styler M. Hepatocellular Carcinoma: First Manifestation as Solitary Humeral Bone Metastasis. Case Rep Oncol Med 2020;2020:8254236. [PMID: 33343953 DOI: 10.1155/2020/8254236] [Reference Citation Analysis]
642 Xu J, Zheng L, Chen J, Sun Y, Lin H, Jin RA, Tang M, Liang X, Cai X. Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals. Cell Death Dis 2017;8:e3095. [PMID: 29022906 DOI: 10.1038/cddis.2017.411] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
643 Yang G, Wang G, Xiong Y, Sun J, Li W, Tang T, Li J. CDC20 promotes the progression of hepatocellular carcinoma by regulating epithelial‑mesenchymal transition. Mol Med Rep 2021;24:483. [PMID: 33907851 DOI: 10.3892/mmr.2021.12122] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
644 Lemke AJ, Chopra SS, Niehues SM, Felix R. [Ultrasound contrast agents for liver diagnostics]. Radiologe 2005;45:520-8. [PMID: 15912323 DOI: 10.1007/s00117-005-1214-1] [Reference Citation Analysis]
645 Kril LM, Vilchez V, Jiang J, Turcios L, Chen C, Sviripa VM, Zhang W, Liu C, Spear B, Watt DS. N-Aryl benzenesulfonamide inhibitors of [3H]-thymidine incorporation and β-catenin signaling in human hepatocyte-derived Huh-7 carcinoma cells. Bioorg Med Chem Lett. 2015;25:3897-3899. [PMID: 26243371 DOI: 10.1016/j.bmcl.2015.07.040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
646 Zhang HY, Wu QJ, Xie CH, Zhang G. Long-term survival of patients with hepatocellular carcinoma with pulmonary and adrenal metastasis: A case report. Exp Ther Med 2012;3:699-702. [PMID: 22969954 DOI: 10.3892/etm.2012.455] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
647 Li J, Chen JN, Zeng TT, He F, Chen SP, Ma S, Bi J, Zhu XF, Guan XY. CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy. BMC Cancer. 2016;16:15. [PMID: 26758620 DOI: 10.1186/s12885-016-2050-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
648 Csepregi A, Ebert MP, Röcken C, Schneider-Stock R, Hoffmann J, Schulz HU, Roessner A, Malfertheiner P. Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma. BMC Cancer 2010;10:317. [PMID: 20569442 DOI: 10.1186/1471-2407-10-317] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
649 Zhou D, Liang J, Xu LI, He F, Zhou Z, Zhang Y, Chen M. Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization. Oncol Lett 2016;11:2987-94. [PMID: 27123051 DOI: 10.3892/ol.2016.4359] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
650 Sadeghi M, Lahdou I, Oweira H, Daniel V, Terness P, Schmidt J, Weiss KH, Longerich T, Schemmer P, Opelz G, Mehrabi A. Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma. Br J Cancer. 2015;113:756-762. [PMID: 26270232 DOI: 10.1038/bjc.2015.227] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
651 Tsai MC, Huang CC, Wei YC, Liu TT, Lin MT, Yi LN, Lin PR, Wang CC, Chu TH, Hsiao CC, Hu TH, Tai MH. Combined Chibby and β-Catenin Predicts Clinical Outcomes in Patients with Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E2060. [PMID: 32192213 DOI: 10.3390/ijms21062060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
652 Hochnadel I, Kossatz-Boehlert U, Jedicke N, Lenzen H, Manns MP, Yevsa T. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. Hum Vaccin Immunother. 2017;13:2931-2952. [PMID: 29112462 DOI: 10.1080/21645515.2017.1359362] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
653 Lupo L, Panzera P, Giannelli G, Memeo M, Gentile A, Memeo V. Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection? HPB (Oxford). 2007;9:429-434. [PMID: 18345289 DOI: 10.1080/13651820701713758] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 5.0] [Reference Citation Analysis]
654 Chen IP, Ariizumi S, Nakano M, Yamamoto M. Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy. J Gastroenterol 2014;49:117-25. [PMID: 23532638 DOI: 10.1007/s00535-013-0793-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
655 Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, McGlynn KA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007;5:1221-1228. [PMID: 17689296 DOI: 10.1016/j.cgh.2007.05.020] [Cited by in Crossref: 314] [Cited by in F6Publishing: 284] [Article Influence: 20.9] [Reference Citation Analysis]
656 Zhou Y, Xu D, Wu L, Li B. Meta-analysis of anatomic resection versus nonanatomic resection for hepatocellular carcinoma. Langenbecks Arch Surg. 2011;396:1109-1117. [PMID: 21476060 DOI: 10.1007/s00423-011-0784-9] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 6.6] [Reference Citation Analysis]
657 Yang GH, Dai Z, Zhou J. Advance in proteomic study of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2008; 16(22): 2487-2492 [DOI: 10.11569/wcjd.v16.i22.2487] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
658 Jiang H, Wang H, Tan Z, Hu S, Wang H, Shi B, Yang L, Li P, Gu J, Wang H, Li Z. Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III. J Biol Chem 2011;286:5913-20. [PMID: 21163950 DOI: 10.1074/jbc.M110.192252] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
659 Bi J, Zhong C, Li K, Chu H, Wang B. Association study of single nucleotide polymorphisms in XRCC1 gene with risk of hepatocellular carcinoma in Chinese Han population. Biomed Res Int 2013;2013:138785. [PMID: 23984316 DOI: 10.1155/2013/138785] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
660 Park SH, Hong JY, Park HJ, Lee SK. The Antiproliferative Activity of Oxypeucedanin via Induction of G2/M Phase Cell Cycle Arrest and p53-Dependent MDM2/p21 Expression in Human Hepatoma Cells. Molecules 2020;25:E501. [PMID: 31979361 DOI: 10.3390/molecules25030501] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
661 Bonzo JA, Ferry CH, Matsubara T, Kim JH, Gonzalez FJ. Suppression of hepatocyte proliferation by hepatocyte nuclear factor 4α in adult mice. J Biol Chem. 2012;287:7345-7356. [PMID: 22241473 DOI: 10.1074/jbc.m111.334599] [Cited by in Crossref: 127] [Cited by in F6Publishing: 86] [Article Influence: 12.7] [Reference Citation Analysis]
662 Diouf M, Bonnetain F, Barbare JC, Bouché O, Dahan L, Paoletti X, Filleron T. Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma. Oncologist 2015;20:62-71. [PMID: 25542450 DOI: 10.1634/theoncologist.2014-0175] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
663 Yoshiji H, Noguchi R, Kitade M, Kaji K, Ikenaka Y, Namisaki T, Yoshii J, Yanase K, Yamazaki M, Tsujimoto T, Akahane T, Kawaratani H, Uemura M, Fukui H. Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J Gastroenterol 2009;44:483-91. [DOI: 10.1007/s00535-009-0031-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
664 Gao J, Duan Z, Zhang L, Huang X, Long L, Tu J, Liang H, Zhang Y, Shen T, Lu F. Failure recovery of circulating NKG2D+CD56dimNK cells in HBV-associated hepatocellular carcinoma after hepatectomy predicts early recurrence. Oncoimmunology 2016;5:e1048061. [PMID: 26942056 DOI: 10.1080/2162402X.2015.1048061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
665 Ishikawa K, Chiba T, Ooka Y, Suzuki E, Ogasawara S, Maeda T, Yokoyama M, Inoue M, Wakamatsu T, Kusakabe Y, Saito T, Tawada A, Arai M, Kanda T, Maruyama H, Imazeki F, Kato N. Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma. Oncotarget 2018;9:21560-8. [PMID: 29765560 DOI: 10.18632/oncotarget.25108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
666 Belghiti J, Kianmanesh R. Surgical treatment of hepatocellular carcinoma. HPB (Oxford). 2005;7:42-49. [PMID: 18333160 DOI: 10.1080/13651820410024067] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 6.8] [Reference Citation Analysis]
667 Sheng Z, Wang X, Xu G, Shan G, Chen L. Analyses of a Panel of Transcripts Identified From a Small Sample Size and Construction of RNA Networks in Hepatocellular Carcinoma. Front Genet 2019;10:431. [PMID: 31156698 DOI: 10.3389/fgene.2019.00431] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
668 Kamino H, Yamazaki Y, Saito K, Takizawa D, Kakizaki S, Moore R, Negishi M. Nuclear receptor CAR-regulated expression of the FAM84A gene during the development of mouse liver tumors. Int J Oncol 2011;38:1511-20. [PMID: 21424122 DOI: 10.3892/ijo.2011.980] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.1] [Reference Citation Analysis]
669 Liu J, Tang SX. Molecular mechanisms behind anti-cancer effects of curcumin in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2013; 21(33): 3678-3682 [DOI: 10.11569/wcjd.v21.i33.3678] [Reference Citation Analysis]
670 Matsuzaki K. Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells. Cell Tissue Res 2012;347:225-43. [PMID: 21626291 DOI: 10.1007/s004